<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28420080</article-id>
<article-id pub-id-type="pmc">5412412</article-id>
<article-id pub-id-type="doi">10.3390/ijms18040828</article-id>
<article-id pub-id-type="publisher-id">ijms-18-00828</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Delineating the Common Biological Pathways Perturbed by ASD’s Genetic Etiology: Lessons from Network-Based Studies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Oron</surname>
<given-names>Oded</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elliott</surname>
<given-names>Evan</given-names>
</name>
<xref ref-type="corresp" rid="c1-ijms-18-00828">*</xref>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Butler</surname>
<given-names>Merlin G.</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<aff id="af1-ijms-18-00828">Molecular and Behavioral Neurosciences Lab, Bar-Ilan University, Faculty of Medicine, 13215 Safed, Israel; <email>odedoron@gmail.com</email></aff>
<author-notes>
<corresp id="c1-ijms-18-00828"><label>*</label>Correspondence: <email>evan.elliott@biu.ac.il</email>; Tel.: +972-72-264-4968</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>4</month>
<year>2017</year>
</pub-date>
<volume>18</volume>
<issue>4</issue>
<elocation-id>828</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>4</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 by the authors.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>In recent decades it has become clear that Autism Spectrum Disorder (ASD) possesses a diverse and heterogeneous genetic etiology. Aberrations in hundreds of genes have been associated with ASD so far, which include both rare and common variations. While one may expect that these genes converge on specific common molecular pathways, which drive the development of the core ASD characteristics, the task of elucidating these common molecular pathways has been proven to be challenging. Several studies have combined genetic analysis with bioinformatical techniques to uncover molecular mechanisms that are specifically targeted by autism-associated genetic aberrations. Recently, several analysis have suggested that particular signaling mechanisms, including the Wnt and Ca<sup>2+</sup>/Calmodulin-signaling pathways are often targeted by autism-associated mutations. In this review, we discuss several studies that determine specific molecular pathways affected by autism-associated mutations, and then discuss more in-depth into the biological roles of a few of these pathways, and how they may be involved in the development of ASD. Considering that these pathways may be targeted by specific pharmacological intervention, they may prove to be important therapeutic targets for the treatment of ASD.</p>
</abstract>
<kwd-group>
<kwd>ASD</kwd>
<kwd>autism</kwd>
<kwd>networks</kwd>
<kwd>genetics</kwd>
<kwd>Fragile-X Syndrome</kwd>
<kwd>Wnt</kwd>
<kwd>mTOR</kwd>
<kwd>Calmodulin</kwd>
<kwd>Calcium</kwd>
<kwd>NGF</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-18-00828">
<title>1. The Genetic Basis of Autism</title>
<p>Autism Spectrum Disorder (ASD) is a developmental disorder characterized by persistent deficits in social communication, as well as restricted and repetitive patterns of behavior. It has been well characterized that genetic aberrations have a prominent role in the etiology of ASD [<xref ref-type="bibr" rid="B1-ijms-18-00828">1</xref>]. Among the first studies to support a genetic etiology were twin studies published in the 1970s by Folstein and Rutter [<xref ref-type="bibr" rid="B2-ijms-18-00828">2</xref>,<xref ref-type="bibr" rid="B3-ijms-18-00828">3</xref>]. A recent meta-analysis by Rutter, encompassing a total of 6413 twins, showed that the heritability rate in families with an autistic proband was in the range of 64–91% [<xref ref-type="bibr" rid="B4-ijms-18-00828">4</xref>]. Furthermore, it has been well-established that ASD overlaps at both the behavioral and genetic levels with other disorders such as social anxiety, Attention Deficit and Hyperactivity Disorder (ADHD), Intellectual Disability (ID), bipolar disorder and schizophrenia [<xref ref-type="bibr" rid="B5-ijms-18-00828">5</xref>,<xref ref-type="bibr" rid="B6-ijms-18-00828">6</xref>,<xref ref-type="bibr" rid="B7-ijms-18-00828">7</xref>,<xref ref-type="bibr" rid="B8-ijms-18-00828">8</xref>]. For example, Khazanda et al. discovered 23 genes, many of which are involved in circadian entrainment, that are associated with ASD, bipolar disorder and schizophrenia, therefore demonstrating shared genes and genetic pathways between various psychiatric disorders [<xref ref-type="bibr" rid="B7-ijms-18-00828">7</xref>]. As such, common behavioral phenotypes of these disorders may have a root in shared genetic etiology. </p>
<p>A heterogeneous genetic etiology for ASD has been firmly established. Historically, some of the first genes that were successfully associated to autism were those responsible for syndromic forms of autism. Thus far, approximately 35 such syndromes have been documented [<xref ref-type="bibr" rid="B9-ijms-18-00828">9</xref>]. A sub-group of these syndromic autisms are mendelian monogenic, and consistently develop due to rare mutations. For example, in the case of Fragile-X Syndrome (FXS), which develops due to aberrations in the Fragile-X Mental Retardation 1 (<italic>FMR1</italic>) gene, up to 30% of these male patients also develop ASD [<xref ref-type="bibr" rid="B10-ijms-18-00828">10</xref>]. Cortical Dysplasia-focal Epilepsy (CDFE) syndrome is caused by mutations in Contactin Associated Protein 2 (<italic>CNTNAP2</italic>), where a subgroup of patients express autistic behavior [<xref ref-type="bibr" rid="B11-ijms-18-00828">11</xref>]. Tuberous sclerosis is caused by mutations in either Tuberous Sclerosis 1/2 (<italic>TSC1</italic>/<italic>TCS2</italic>), where up to 61% of patients express autistic behaviors [<xref ref-type="bibr" rid="B12-ijms-18-00828">12</xref>]. Rett syndrome, which includes autistic behavior, is caused by mutations in the Methyl CpG binding protein 2 (<italic>MECP2</italic>) [<xref ref-type="bibr" rid="B13-ijms-18-00828">13</xref>]. Another group of syndromic autisms arise from Copy Number Variations (CNV) [<xref ref-type="bibr" rid="B14-ijms-18-00828">14</xref>], which contain large duplication/deletion loci that usually encompass several genes, yet the causative gene is often not known. One such example is Phelan-McDermid syndrome where up to 9 Mb are deleted at Chr22q13 encompassing up to 130 genes [<xref ref-type="bibr" rid="B15-ijms-18-00828">15</xref>]. The most notable gene in this CNV is <italic>SHANK3</italic>/<italic>PROSAP2</italic>, where mutations in this gene alone have been shown to be associated with ASD [<xref ref-type="bibr" rid="B16-ijms-18-00828">16</xref>,<xref ref-type="bibr" rid="B17-ijms-18-00828">17</xref>]. Additional CNVs include the 15q11-13 deletion or duplication syndromes [<xref ref-type="bibr" rid="B18-ijms-18-00828">18</xref>], the chromosome 16p11.2 deletion or duplication syndromes [<xref ref-type="bibr" rid="B19-ijms-18-00828">19</xref>,<xref ref-type="bibr" rid="B20-ijms-18-00828">20</xref>] and the 2q23.1 microdeletion syndrome [<xref ref-type="bibr" rid="B7-ijms-18-00828">7</xref>]. Most syndromic autisms, such as CDFE, TSC or the 2q23.1 microdeletion syndrome are considered extremely rare, however the highest discovery rate observed in FXS accounts for no more than 2% of autistic cases [<xref ref-type="bibr" rid="B9-ijms-18-00828">9</xref>].</p>
<p>A wider search for ASD’s genetic etiology started with linkage studies, which uncovered several candidate loci, including 2q, 3q 7q and 20p. However, it was primarily through Next Generation Sequencing (NGS) technologies that majority of genes were discovered, and by 2012, 10–20% of ASD cases had a known genetic link [<xref ref-type="bibr" rid="B9-ijms-18-00828">9</xref>]. One approach for locating new genetic candidates involved in ASD development is to determine de-novo mutations in gene coding regions, usually found in sporadic familial cases. In 2011, O’Roak et al. conducted the first exome-wide sequencing study in ASD on 20 sporadic cases, revealing de-novo mutations in <italic>FOXP1</italic>, <italic>GRIN2B</italic>, <italic>SCN1A</italic> and <italic>LAMC3</italic> [<xref ref-type="bibr" rid="B21-ijms-18-00828">21</xref>]. In 2012, in an effort to discover de-novo mutations, the Simons Simplex Collection conducted three large exome-sequencing trails which included approximately 750 families with affected and unaffected siblings. Many promising genes were identified, including <italic>SCN2A</italic>, <italic>CHD8</italic> and <italic>NTNG1</italic> [<xref ref-type="bibr" rid="B22-ijms-18-00828">22</xref>,<xref ref-type="bibr" rid="B23-ijms-18-00828">23</xref>,<xref ref-type="bibr" rid="B24-ijms-18-00828">24</xref>]. By that time, it had become increasingly clear that genetic mutations involved in ASD do not fall into one particular biological category, but seem to be found in genes involved in several different biological systems. In recent years, whole genome sequencing studies are also beginning to appear, which aim to discover genetic aberrations in both coding and noncoding regions. One such study, by Yuen et al., found genetic aberrations in <italic>STXBP1</italic>, <italic>UBE3A</italic>, <italic>KATNAL2</italic>, <italic>THRA</italic>, <italic>KCNQ4</italic>, <italic>MYH14</italic>, <italic>GJB6</italic> and <italic>COL11A1</italic>, some of which have been previously associated with ASD and some with overlapping conditions such as hearing loss [<xref ref-type="bibr" rid="B25-ijms-18-00828">25</xref>]. In addition, several Genome-Wide Association Studies (GWAS) emphasized the significance of common genetic variation to the inheritance of autistic traits [<xref ref-type="bibr" rid="B26-ijms-18-00828">26</xref>]. </p>
<p>To this day, over 800 genes have been identified and associated with ASD development [<xref ref-type="bibr" rid="B27-ijms-18-00828">27</xref>]. Given this heterogeneous genetic reality, it has been hypothesized that the multitude of genetic aberrations are affecting specific molecular pathways that might be in common across the autistic spectrum, and are responsible for dysregulated neurodevelopment [<xref ref-type="bibr" rid="B28-ijms-18-00828">28</xref>]. Discovering such common pathways has proven to be challenging. To address this difficulty, it is appropriate to perform network-based analysis of autism associated genes [<xref ref-type="bibr" rid="B29-ijms-18-00828">29</xref>]. In the following chapters, we will discuss attempts at using network-based approaches to discover candidate signaling pathways that are effected by ASD-associated genetic aberrations, and how these signaling pathways may be involved in dysregulated neurodevelopment and the phenotypes of ASD.</p>
</sec>
<sec id="sec2-ijms-18-00828">
<title>2. Searching for Common Molecular Targets of Autism Mutations</title>
<sec id="sec2dot1-ijms-18-00828">
<title>2.1. Protein–Protein Network Analysis and Pathways Enrichment Tools</title>
<p>One approach to discovering molecular pathways that are commonly targeted by autism-associated mutations is to perform Protein-Protein Interaction (PPI) network analysis to identify groups of proteins within a given list of proteins that physically interact with each other. This analysis uses different databases that curate experimentally validated or predicted protein-protein interactions [<xref ref-type="bibr" rid="B29-ijms-18-00828">29</xref>]. PPI also identifies hubs, highly interconnected proteins, which might prove to be central in the molecular pathway. However, this approach has some disadvantages and biases. First, tissue specific PPI databases are scarce, which are necessary to understand protein interactions in specific tissues, such as the brain. A very partial solution to this problem is to combine PPI databases with RNA expression from the specific tissue, therefore making sure that you only take into account proteins which are found in that specific tissue. Additional tools used to reveal biologically-relevant pathways within a gene list are gene ontology databases and signaling pathway enrichment tools. The Gene Ontology project initiated by the Gene Ontology Consortium (GOC) strives to provide a unifying vocabulary to genes and their biological roles [<xref ref-type="bibr" rid="B30-ijms-18-00828">30</xref>]. In addition, there is a growing number of signaling pathway enrichment tools available for free or through commercial license [<xref ref-type="bibr" rid="B31-ijms-18-00828">31</xref>]. There are several differences that should be considered when using these tools, such as method of data curation (manually and computerized), algorithms used to generate signaling pathway maps, types of pathway maps (e.g., disease specific, kinase signaling, hormone mediated) and breadth of knowledgebase. For example, in the next section, we mention studies which used KEGG and IPA pathway enrichment tools to generate pathways that might be affected in ASD. Due to the fact that IPA is a commercial tool, it is difficult to thoroughly compare it to other tools, and thus, reviews conducting such comparisons lack information about IPA. However, one important difference between KEGG and IPA is the size of their knowledgebase. KEGG mainly curates interaction and reactions of molecular pathways from the literature, while IPA also imports data from several external databases, which increases its knowledgebase substantially [<xref ref-type="bibr" rid="B32-ijms-18-00828">32</xref>,<xref ref-type="bibr" rid="B33-ijms-18-00828">33</xref>]. Therefore, it is necessary to integrate knowledge from several different pathway analysis tools in order to discover biological pathways that are commonly targeted by autism-associated mutations.</p>
</sec>
<sec id="sec2dot2-ijms-18-00828">
<title>2.2. Autism-Associated Signaling Pathways Discovered Using Network Analysis and Pathway Enrichment Tools</title>
<p>As part of the effort conducted by the SSC in 2012, O’Roak et al. sequenced the exome of 209 families with sporadic cases of ASD, revealing 126 genes which had truncation or missense mutations, followed by PPI analysis, to determine if these genes form a biologically-relevant network [<xref ref-type="bibr" rid="B23-ijms-18-00828">23</xref>]. They discovered one highly interconnected cluster of mutated genes, which included genes involved both in chromatin-binding and β-catenin function. An additional network analysis conducted with the IPA tool enriched 8 Wnt-signaling regulators, which are involved in the regulation of β-catenin, as we will explain later. Therefore, combination of exome sequencing with downstream network analysis revealed an autism-associated molecular pathway, the Wnt-β-catenin pathway. This was not the first study to suggest the involvement of Wnt-signaling in ASD [<xref ref-type="bibr" rid="B34-ijms-18-00828">34</xref>,<xref ref-type="bibr" rid="B35-ijms-18-00828">35</xref>], however it strongly demonstrated that network analysis may reveal pathways that are highly important for further research. In a 2014 follow up bioinformatics study which included the combined data for the O’Roak et al. study, and two other de-novo ASD mutation studies that were published in the same issue of <italic>Nature</italic>, a subset of these de-novo mutations were enriched for genes involved in chromatin-binding [<xref ref-type="bibr" rid="B36-ijms-18-00828">36</xref>]. A separate study collected genome association data of rare CNVs from 6742 ASD patients, and constructed PPI networks based on the genes deleted or duplicated due to the CNVs. Calmodulin1, which is a major regulator of Calcium-signaling, was found as a central hub in the PPI network [<xref ref-type="bibr" rid="B37-ijms-18-00828">37</xref>]. An additional network analysis of autism-associated genes has suggested a role for both Wnt and calcium pathways in ASD. Wen et al. performed KEGG pathway analysis on the SFARI annotated list of autism-associated genes. They found that these genes were particularly enriched for biological pathways including Calcium-signaling, Wnt-signaling, mTOR, and cellular adhesion molecules [<xref ref-type="bibr" rid="B38-ijms-18-00828">38</xref>]. </p>
<p>A different strategy to identify molecular pathways that are dysregulated by autism-associated mutations is to use publicly available data of gene expression patterns in the human brain to build gene expression networks and PPI networks that are found in specific brain regions, and then to probe if any of these networks are enriched for autism-associated genes, and are therefore likely to be perturbed by autism-related mutations. Lin et al. used such an approach to identify PPI networks in the brain that are effected by the autism-associated CNV at chromosome 16p11.2 [<xref ref-type="bibr" rid="B39-ijms-18-00828">39</xref>]. Using published databases of gene expression and protein interaction data, the authors built protein interaction networks that appear in specific brain regions, and at specific developmental time points. The authors then discovered that four of these protein interaction networks would be disrupted by the CNV, particularly during mid-fetal stage and in early childhood. Gene ontology analysis of these protein networks showed enrichment for Wnt-signaling and NGF-signaling. A similar method was used to discover human brain protein networks dysregulated by rare or common variants associated with autism. Ben-David et al., built brain-region specific gene co-expression modules using WGCNA [<xref ref-type="bibr" rid="B40-ijms-18-00828">40</xref>]. They found that a co-expression module that was highly effected by both rare and common autism-associated variants was enriched for genes involved in synaptic transmission and the Calmodulin-binding pathway. To summarize, these studies used different methodologies to uncover molecular pathways targeted by ASD mutations and implicated the Wnt-signaling and Ca<sup>2+</sup>/Calmodulin-signaling [<xref ref-type="bibr" rid="B37-ijms-18-00828">37</xref>,<xref ref-type="bibr" rid="B38-ijms-18-00828">38</xref>,<xref ref-type="bibr" rid="B39-ijms-18-00828">39</xref>,<xref ref-type="bibr" rid="B40-ijms-18-00828">40</xref>]. Therefore, we will focus on defining these two specific pathways and how they may be related to the autism phenotype, followed by a short discussion of some of the other pathways identified.</p>
</sec>
</sec>
<sec id="sec3-ijms-18-00828">
<title>3. Wnt-Signaling</title>
<sec id="sec3dot1-ijms-18-00828">
<title>3.1. Roles for Wnt-Signaling in Neurodevelopment and Adult Brain</title>
<p>Wnt-signaling pathways orchestrate cellular proliferation, polarity and differentiation; processes that are crucial for healthy tissue morphogenesis, especially in the embryonic stage [<xref ref-type="bibr" rid="B41-ijms-18-00828">41</xref>]. Dysregulation of these pathways have been implicated in a wide variety of cancers, as well as in other pathologies, such as type II diabetes, osteoporosis and heart conditions [<xref ref-type="bibr" rid="B41-ijms-18-00828">41</xref>,<xref ref-type="bibr" rid="B42-ijms-18-00828">42</xref>]. In humans there are 19 Wnt glycoprotein ligands, which activate signal transduction pathways through binding to one of the 10 Frizzled receptors. As of today, there are two extensively researched Wnt pathways; a canonical pathway and a non-canonical pathway. In the canonical pathway the secreted Wnt glycoproteins bind to Frizzled receptors, as well as either the LRP6 or LRP5 co-receptors, to initiate a signaling cascade. The activated receptor recruits the scaffolding protein Dishevelled, which recruits and sequesters the Axin-GSK3β-APC destruction complex, thus preventing its role in phosphorylating β-catenin, leaving it stable for downstream activity. Stabilized β-catenin is transported to the nucleus where it fulfills its role as a co-transcription factor by binding to the TCF/LEF transcription factors, or it relocates to the cellular membrane where it maintains cell-cell adhesion complexes [<xref ref-type="bibr" rid="B41-ijms-18-00828">41</xref>,<xref ref-type="bibr" rid="B42-ijms-18-00828">42</xref>]. The two non-canonical Wnt pathways are independent of β-catenin, and include the Wnt/JNK pathway, which drives polarized cell movements such as neuronal crest migration, as well as the Wnt/Calcium pathway that has been shown to be involved in cardiac development [<xref ref-type="bibr" rid="B43-ijms-18-00828">43</xref>]. </p>
<p>Canonical Wnt-signaling has a pivotal role both in the developing and mature brain. Much evidence has indicated that during development the Wnt pathway regulates the balance between proliferation and differentiation of neuronal progenitor and precursor cells, as was recently reviewed by Noelanders and Vleminckx [<xref ref-type="bibr" rid="B44-ijms-18-00828">44</xref>]. In transgenic mice with overexpression of stabilized β-catenin, neuronal precursor cells in the ventricular zone continue to divide beyond their natural timeframe, resulting in enlarged brains and deeper sulci folds that resemble higher mammals [<xref ref-type="bibr" rid="B45-ijms-18-00828">45</xref>]. Concurrently, inhibition of β-catenin during embryonic development leads to premature differentiation of precursors to neurons [<xref ref-type="bibr" rid="B46-ijms-18-00828">46</xref>]. These studies suggest that Wnt-signaling promotes proliferation of neuronal precursors and delays their differentiation. There is some evidence suggesting Wnt-signaling may inhibit proliferation in certain circumstances. For example, as shown in developing zebrafish, induced activation of Wnt8 reduced the population of neuronal progenitor in the hypothalamus; reduction in neuronal progenitors was also induced by the canonical Wnt pathway activator, BIO [<xref ref-type="bibr" rid="B47-ijms-18-00828">47</xref>]. These studies suggest that Wnt-signaling can regulate neuronal precursor proliferation in a manner that is either species-specific, or cell type-specific. </p>
<p>In addition to its roles in development, Wnt-signaling also affects Neuronal Stem Cell (NSC) proliferation and differentiation in the mature brain. One study of Wnt-signaling in NSCs used mice which express lacZ under the control of a TCF transcription response [<xref ref-type="bibr" rid="B48-ijms-18-00828">48</xref>]. These mice received intraventricular infusions of the mitotic inhibitor Ara-C, which kills the dividing progenitor cells and decreases NSCs; followed with BrdU infusions, which allows the tracking of the regeneration of NSCs in the Subventricular Zone (SVZ). 30% of the BrdU positive cells displayed active Wnt-signaling (LacZ); and when Wnt-signaling was pharmacologically blocked, the number of neurospheres in the SVZ significantly decreased. Wnt-signaling has also been shown to induce NSC proliferation after injury [<xref ref-type="bibr" rid="B48-ijms-18-00828">48</xref>]. Mice subjected to a stroke-inducing surgery (Pial Vessel Disruption, or PVD) displayed an increase in lacZ expressing neuronal stem cells of the SVZ after seven days. Other studies showed that Wnt-signaling is also involved in the differentiation of NSCs in the mature brain. For example, in adult NSCs of the SVZ, Wnt-signaling induces cell-cycle exit in the presence of Hipk1, an interactor of β-catenin. Furthermore, when overexpressing β-catenin and Hipk1, an increase of the cell-cycle inhibitor P16Ink4 was observed [<xref ref-type="bibr" rid="B49-ijms-18-00828">49</xref>]. Therefore, Wnt has a role both in the proliferation and differentiation of NSCs cells in the adult brain.</p>
<p>Apart from its role in NSCs, Wnt-signaling has a positive developmental role in the maturation of dendrites and spines. The α-catenin/β-catenin/<italic>N</italic>-cadherin complex acts as a scaffold between intracellular actin and extracellular cadherin-dependent interactions [<xref ref-type="bibr" rid="B50-ijms-18-00828">50</xref>,<xref ref-type="bibr" rid="B51-ijms-18-00828">51</xref>]. This role is important for dendrite arborization in the developing brain, as demonstrated by the fact that overexpression of β-catenin, α-catenin and <italic>N</italic>-cadherin individually, and co-expression of β-catenin and <italic>N</italic>-cadherin in vitro, both induce increased dendritic branching [<xref ref-type="bibr" rid="B52-ijms-18-00828">52</xref>]. In addition, β-catenin has also been implicated in spine pruning and maturation as part of the β-catenin/<italic>N</italic>-cadherin complex. By inducing a conditional knockout of β-catenin in the cerebral cortex and hippocampus of mice, spine density is increased and is comprised mostly from immature spines [<xref ref-type="bibr" rid="B53-ijms-18-00828">53</xref>]. This suggests that pruning of immature spines may be dependent on β-catenin function. </p>
<p>In addition to the roles in neuronal differentiation and morphology, β-catenin has been suggested to have an additional role in neurotransmission through two distinct mechanisms. First, translocation of β-catenin to spines may increase the size of the post synaptic density (PSD) which leads to increased synaptic transmission [<xref ref-type="bibr" rid="B54-ijms-18-00828">54</xref>]. This was shown by inducing a point mutation, which prevents the phosphorylation of Tyr654 in β-catenin, and results in its increased localization to spines. Considering the role of β-catenin in the α-catenin/β-catenin/<italic>N</italic>-cadherin complex, and the complex’s importance in inducing cell-cell contacts [<xref ref-type="bibr" rid="B55-ijms-18-00828">55</xref>], the authors deciphered if increased presence of β-catenin in spines might increase synaptic contacts, and affect other properties such as postsynaptic morphology and neurotransmission. Interestingly, they observed more intense and larger PSD-95 puncta and increased mEPSCs. Second, in the presynaptic neuron, β-catenin has been shown to have a role in recruiting vesicles to the presynaptic membrane: β-catenin has a PDZ domain used to recruit PDZ domain containing proteins such as Veli and Cadherin clusters [<xref ref-type="bibr" rid="B56-ijms-18-00828">56</xref>]. Veli has been shown to create a tripartite complex with CASK and Mint1, which binds Munc18-1. This complex is essential for vesicle docking to the plasma membrane [<xref ref-type="bibr" rid="B57-ijms-18-00828">57</xref>,<xref ref-type="bibr" rid="B58-ijms-18-00828">58</xref>]. It has also been shown that regulation of synaptic vesicle release into the synaptic cleft is important for healthy development of synaptic plasticity in 4–8 day old rats [<xref ref-type="bibr" rid="B59-ijms-18-00828">59</xref>]. In that regard, β-catenin is suggested to have an essential role. This has been shown by siRNA-mediated knockdown of synaptic β-catenin, which increased spillage of vesicle content into the synaptic cleft in nascent presynaptic terminals [<xref ref-type="bibr" rid="B60-ijms-18-00828">60</xref>]. An additional study revealed that neuronal cultures treated with Wnt8A-conditioned media displayed increased PSD95 puncta, and that the co-receptor LRP6 selectively localizes to excitatory synapses where it takes part in regulating excitatory synaptic development [<xref ref-type="bibr" rid="B61-ijms-18-00828">61</xref>]. These studies show that Wnt-signaling, and in particular β-catenin, is essential for normal brain development as well as adult brain performance.</p>
</sec>
<sec id="sec3dot2-ijms-18-00828">
<title>3.2. How Wnt-Signaling May Be Involved in ASD</title>
<p>From the known roles of Wnt-signaling in neuronal differentiation, morphology, and neurotransmission, we can propose possible roles for dysregulated Wnt-signaling in the processes that are dysregulated in the brain of individuals diagnosed with ASD. Numerous studies have witnessed differences in cortical patterning or spine morphology in the brain of individuals with ASD. In some cases, it has been shown that cortical dendritic spine density is increased in the brain of individuals with autism [<xref ref-type="bibr" rid="B62-ijms-18-00828">62</xref>]. This matches the phenotype of the β-catenin knockout mice, which displays increased spines [<xref ref-type="bibr" rid="B53-ijms-18-00828">53</xref>]. However, it is not clear if the increase in spine density in the ASD brain is due to an increase in immature spines, as is in the case of the knockout mice. In addition, studies have shown dysregulation of cytoarchitecture in the cortex and in the architecture of the microcolumns in the cortex of individuals diagnosed with ASD [<xref ref-type="bibr" rid="B63-ijms-18-00828">63</xref>,<xref ref-type="bibr" rid="B64-ijms-18-00828">64</xref>]. A separate study, using the three dimensional imaging technique CLARITY, determined abnormal connections between axons in the brain of individuals with ASD [<xref ref-type="bibr" rid="B65-ijms-18-00828">65</xref>]. Considering that dysregulation of Wnt-signaling affects development of normal cortical architecture, as well as neuronal morphology, it is possible that dysregulated Wnt-signaling is involved in these dysregulations in the ASD brain. </p>
<p>Experimentation in mouse models have also given more insight into the possible roles of Wnt in the development of ASD. Interestingly, a conditional knockdown of β-catenin in Parvalbumin (PV) neurons in mice induced increased repetitive behaviors and anxiety, decreased social interaction, and an increase in PV neuron density in the prefrontal cortex [<xref ref-type="bibr" rid="B66-ijms-18-00828">66</xref>]. An additional Wnt-signaling component, Glycogen Synthase Kinase-3 (GSK3) was recently reviewed as a key driver of ASD development, as well as a therapeutic target for FXS [<xref ref-type="bibr" rid="B67-ijms-18-00828">67</xref>,<xref ref-type="bibr" rid="B68-ijms-18-00828">68</xref>]. GSK3 is hyperactive in several brain regions of the FXS mouse model [<xref ref-type="bibr" rid="B69-ijms-18-00828">69</xref>] and impaired social preference and exaggerated anxiety during social interaction have been recorded in a GSK3 knockin mouse model [<xref ref-type="bibr" rid="B35-ijms-18-00828">35</xref>]. So using this model, researchers inhibited GSK3 functioning in the hippocampus to explore how its hyperactivity contributes to FXS phenotypes. Both novel object detection and hippocampal learning, which are deficient in this mouse model, were rescued [<xref ref-type="bibr" rid="B70-ijms-18-00828">70</xref>,<xref ref-type="bibr" rid="B71-ijms-18-00828">71</xref>]. These studies suggest a direct link between Wnt-signaling and autism-like behavior in autism mouse models.</p>
<p>In addition, recent studies in mouse models have determined how autism-related mutations may induce autism-related behaviors through the dysregulation of Wnt-signaling. One such example is <italic>CHD8</italic>, a gene that was recently found to be strongly associated to ASD and encodes for a chromatin-binding protein. One of the first studies on CHD8 in the brain shows that it acts as a positive regulator of the Wnt pathway in the brain [<xref ref-type="bibr" rid="B72-ijms-18-00828">72</xref>]. CHD8 binds to the promoter regions of Fzd1, Dvl3 and β-catenin. Knockdown of CHD8 during cortical development results in their downregulation, leading to the reduction of the TCF/LEF transcription factor family and ultimately defective brain development. By expressing a degradation-resistant β-catenin construct in CHD8-downregulated embryos, researchers rescued the aberrant dendritic arborization as well as increased spine density in the CHD8-downregulated mice. In addition, the study showed that inducing stable β-catenin restores the aberrant social and anxiogenic behaviors to the levels seen in control mice. The Shank scaffolding family is an additional group of high-risk ASD genes that have been suggested to interact with Wnt-signaling components. In a recent publication by Harris et al., a Shank-knockout drosophila model was used to study of the potential molecular pathways that the Shank family of genes regulate [<xref ref-type="bibr" rid="B73-ijms-18-00828">73</xref>]. Surprisingly, the study revealed that the non-canonical Wnt-Frizzled Nuclear Import (FNI) pathway was affected. In this pathway, Wnt binding induces internalization of the Fz2 receptor, followed by proteolytic cleavage of the receptors’ N-terminus to form Fz2-C, which translocates into the nucleus, where it regulates transcription necessary for synaptic development [<xref ref-type="bibr" rid="B74-ijms-18-00828">74</xref>,<xref ref-type="bibr" rid="B75-ijms-18-00828">75</xref>]. By knocking out Shank family genes, Harris et al. revealed reduction of the Fz2 internalization into the post-synaptic membrane, reduction of Fz2-C presence in the nucleus, and abnormal synaptic development. Therefore, there is accumulating evidence that autism-associated mutations affect abnormal cortical patterning, synaptic development, and autism-like behaviors through modulation of Wnt-signaling pathway.</p>
</sec>
</sec>
<sec id="sec4-ijms-18-00828">
<title>4. Calcium and Calmodulin Signaling</title>
<sec id="sec4dot1-ijms-18-00828">
<title>4.1. Roles of Calcium-Signaling and the Calmodulin-Binding Pathway in the Brain</title>
<p>Shifts in Calcium (Ca<sup>2+</sup>) concentrations have been shown to affect the function of several tissues and organs such as the heart, pancreas and components of the Central Nervous System (CNS). Therefore, it is of no surprise that disequilibrium in signaling leads to pathology [<xref ref-type="bibr" rid="B76-ijms-18-00828">76</xref>]. In the brain, Ca<sup>2+</sup> performs specific functions in the presynapse and postsynapse. In the presynapse, arrival of action potentials induce an increase of presynaptic Ca<sup>2+</sup> levels through activation of the N and P/Q-voltage-gated channel. The influx of Ca<sup>2+</sup> leads directly to the release of neurotransmitters [<xref ref-type="bibr" rid="B77-ijms-18-00828">77</xref>]. However, the role of Ca<sup>2+</sup> in postsynaptic signal transduction pathways has been found to be dysregulated in the autism genetic studies discussed previously. </p>
<p>Ca<sup>2+</sup>-induced effects in postsynaptic neuronal function and excitability are mediated through its binding with the protein Calmodulin (CaM; Ca<sup>2+</sup>-Modulated protein), which induces signaling to additional downstream CaM Kinases [<xref ref-type="bibr" rid="B77-ijms-18-00828">77</xref>,<xref ref-type="bibr" rid="B78-ijms-18-00828">78</xref>]. Glutamic acid induces Ca<sup>2+</sup> influx at the postsynapse by binding to <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors (NMDARs) and metabotropic glutamate receptors such as mGlur1, which initiates the release of internal Ca<sup>2+</sup> stores [<xref ref-type="bibr" rid="B77-ijms-18-00828">77</xref>]. After binding Ca<sup>2+</sup>, CaM may induce the activation of CaMKII or CaMKK2. CaMKII is a dodecamer holoenzyme which has 28 isoforms composed of four different subunits (CaMKIIα through δ), and resides mostly in spines and dendritic shafts of excitatory neurons [<xref ref-type="bibr" rid="B79-ijms-18-00828">79</xref>,<xref ref-type="bibr" rid="B80-ijms-18-00828">80</xref>,<xref ref-type="bibr" rid="B81-ijms-18-00828">81</xref>]. The mandatory role of CaMKII in synaptic function has been well described [<xref ref-type="bibr" rid="B82-ijms-18-00828">82</xref>]. Active CaM binds to CaMKII subunits and relieves them from autoinhibition, which leads to autophosphorylation and kinase activity [<xref ref-type="bibr" rid="B78-ijms-18-00828">78</xref>]. CaMKIIα kinase activity is mandatory for long-term potentiation (LTP), the main electrophysiological determinant of experience-dependent synaptic strengthening, and is highly involved in behavioral processes, such as learning and memory. Deletion of <italic>CAMKIIA</italic>, or inhibiting the binding of CaM and Ca<sup>2+</sup> to CaMKII, inhibits LTP induction [<xref ref-type="bibr" rid="B83-ijms-18-00828">83</xref>]. CaMKIIβ has been shown to interact with cytoskeleton subunits such as F-actin, α-catinin and the PSD protein Densin-180 for the purpose of spine size regulation, as well as to affect long-term synaptic plasticity by binding and regulating receptors such as GluN2B and GluA1 [<xref ref-type="bibr" rid="B80-ijms-18-00828">80</xref>,<xref ref-type="bibr" rid="B82-ijms-18-00828">82</xref>]. Furthermore, accumulating evidence show that CaMKII phosphorylates the GABA<sub>A</sub> β, γ2 and α1 subunits, and regulates GABA<sub>A</sub> trafficking to the synaptic membrane [<xref ref-type="bibr" rid="B84-ijms-18-00828">84</xref>]. Since GABA is the major inhibitory neurotransmitter, these findings highlight that CaMKII plays important roles in both excitatory and inhibitory neurotransmission. </p>
<p>CaM also activates CaMKK2, whose activity is crucial for spatial memory formation, and the downstream activation of additional kinases: CaMKI is a positive transducer of growth cone motility which is essential for neurite elongation and arborization [<xref ref-type="bibr" rid="B85-ijms-18-00828">85</xref>]; phosphorylation of CaMKIV increases gene expression and protein synthesis, and is also necessary for contextual fear [<xref ref-type="bibr" rid="B86-ijms-18-00828">86</xref>]. CaMKK2 also phosphorylates other kinases such as the AMP-activated Protein Kinase (AMPK) who’s activity is essential for regulating the energy intake necessary for typical brain function [<xref ref-type="bibr" rid="B87-ijms-18-00828">87</xref>]. Interestingly, <italic>CAMKIG</italic> and <italic>CAMKIV</italic> are among the genes which were enriched in the Calmodulin-binding pathway in the Ben-David et al. publication, which looked for common molecular pathways affected by rare and common variations in ASD [<xref ref-type="bibr" rid="B40-ijms-18-00828">40</xref>]. Overall, this data provides compelling evidence of how Ca<sup>2+</sup> signaling and the CaM pathway are involved in neurological functions by affecting a variety of synaptic characteristics, neurotransmission via excitatory and inhibitory receptor regulation and important biological functions such as LTP and LTM. Deficits in the CaM pathway and its branching cascades have the potential to be involved in many neuropsychiatric conditions due to their broad influence on many biological systems, and more specifically by the way it regulates neurotransmission and synaptic characteristics.</p>
</sec>
<sec id="sec4dot2-ijms-18-00828">
<title>4.2. How Calcium-Signaling and the Calmodulin-Binding Pathway May Be Involved in ASD</title>
<p>Considering the central role of Ca<sup>2+</sup> and CaM signaling in synaptic function and neuronal connectivity, it is reasonable to presume that dysregulation of this pathway could lead to autism-related symptoms. However, it is technically challenging to decipher if there are any dysregulation in synaptic functions such as LTP in humans diagnosed with ASD, while evidence for such dysregulation have been frequently observed in several ASD mouse models [<xref ref-type="bibr" rid="B88-ijms-18-00828">88</xref>,<xref ref-type="bibr" rid="B89-ijms-18-00828">89</xref>]. Therefore, our understanding of the possible role of Ca<sup>2+</sup> signaling in autism is still at its infancy, compared to more established role of the Wnt pathway. Of great interest, one human study has used Transcranial Magnetic Stimulation (TMS) to study changes in long term potentiation-like synaptic plasticity in humans diagnosed with ASD [<xref ref-type="bibr" rid="B90-ijms-18-00828">90</xref>]. In this study, the researchers performed TMS in cortical regions followed by motor-evoked potentials. Individuals with ASD did not show any changes in motor-evoked potentials after TMS, unlike neurotypical controls. This study suggests deficits in plasticity that resemble deficits in LTP. Additional human studies have verified similar deficits in neuronal network connectivity in ASD patients, as has been recently reviewed [<xref ref-type="bibr" rid="B91-ijms-18-00828">91</xref>]. These studies have often found changes in electroencephalographic signals after different sensory stimuli in ASD patients. Overall, these studies suggest deficits in synaptic and network activity that may be related to Calcium-signaling. </p>
<p>While studies of Ca<sup>2+</sup> signaling in the human brain remains challenging, recent studies have determined disturbances in Ca<sup>2+</sup> signaling in cells derived from individuals with ASD. Agonist-evoked Ca<sup>2+</sup> signaling has been shown to be dysfunctional in skin fibroblasts derived from individuals diagnosed with autism [<xref ref-type="bibr" rid="B92-ijms-18-00828">92</xref>]. An elegant study was performed on induced Pluripotent Stem Cells (iPSC) derived from individuals diagnosed with Timothy syndrome [<xref ref-type="bibr" rid="B93-ijms-18-00828">93</xref>], a syndromic autism where 80% of individuals are diagnosed with ASD. These iPSCs were differentiated into neurons in vitro and displayed dysregulated Ca<sup>2+</sup> signaling and changes in activity-dependent gene transcription. While these studies suggest that Ca<sup>2+</sup> signaling and CaM may be involved in the biology of ASD, technological improvements of Ca<sup>2+</sup> imaging in the human brain, and more high-throughput studies in individuals diagnosed with ASD, are necessary to understand the role of Ca<sup>2+</sup> in the specific behaviors and brain regions that are particularly relevant to ASD.</p>
<p>Animal models and in vitro studies have given some additional insights into how dysregulation of Ca<sup>2+</sup> and Calmodulin-binding may be involved in abnormal neurodevelopment. For example, CaMKIV positively regulates the transcription of FMRP (Fragile-X Mental Retardation Protein), the causative gene of FXS [<xref ref-type="bibr" rid="B94-ijms-18-00828">94</xref>]. A follow-up study found that a Single Nucleotide Polymorphism (SNP) in the gene CaMKIV (rs25925) is associated with higher risk for ASD development in a European cohort. This SNP appears to be located on a splicing factor binding site, and is predicted to alter the balance of CaMKIV isoforms [<xref ref-type="bibr" rid="B95-ijms-18-00828">95</xref>]. In addition, CaMKIIα has been shown to regulate the activity of mGluR5, which is a potential target in FXS treatment [<xref ref-type="bibr" rid="B96-ijms-18-00828">96</xref>]. It is still unclear how CaMKIIα perturb mGluR5 activity in FXS, however one proposed mechanism suggests that CaMKIIα is significantly elevated in the synapse of FXS mouse models, which might cause the hyperphosphorylation of the Homer 1 (H1) and 2 (H2) scaffolding proteins, resulting in their dissociation from mGluR5. This dissociation allows the short Homer 1 isoform, H1α, to bind mGluR5 and induce ligand-independent activity of the receptor [<xref ref-type="bibr" rid="B97-ijms-18-00828">97</xref>]. Inhibition of mGluR5 in <italic>FMR1</italic> knockout mice improved learning and memory, which highlighted this therapy as a promising pharmaceutical treatment [<xref ref-type="bibr" rid="B98-ijms-18-00828">98</xref>]. However, clinical trials that were designed to inhibit mGluR5 and its downstream pathways in FXS patients described only partial success, as extensively reviewed by Schaefer, Davenport and Erickson [<xref ref-type="bibr" rid="B99-ijms-18-00828">99</xref>]. In one clinical study, the mGluR5 selective antagonist fenobam induced improvement in prepulse inhibition, but had no effects on the excessive impulsivity observed in FXS patients [<xref ref-type="bibr" rid="B100-ijms-18-00828">100</xref>]. In another clinical study, treatment of a small cohort of FXS patients with Lithium—which mitigates signaling pathways activated via mGluR5 signaling—resulted in significant behavioral improvements such in hyperactivity and inappropriate speech, however induced only a tendency for improvement in irritability, lethargy and repetitive behaviors [<xref ref-type="bibr" rid="B101-ijms-18-00828">101</xref>]. </p>
<p>An additional syndromic autism linked with Ca<sup>2+</sup> signaling dysregulation is Angelman Syndrome (AS), which is characterized by the deletion of the maternal allele of 15q13-11, including the gene <italic>UBE3A</italic>. In the <italic>UBE3A</italic> maternal allele null mouse model, disruptions in the autophosphorylation of CaMKIIα, which is essential for its kinase activity, is responsible for LTP deficits of the hippocampus [<xref ref-type="bibr" rid="B102-ijms-18-00828">102</xref>]. CaMKIIα has also been found to interact directly with scaffolding proteins associated with ASD development. Specifically, using immunoprecipitation to pull-down CaMKII from different neuronal cell fractions of the forebrain, it was determined that CaMKII binds Shank3, Dlgap2 and Syngap1 in the synapse [<xref ref-type="bibr" rid="B103-ijms-18-00828">103</xref>]. In summary, various studies have identified CaMKIV and CaMKIIα as the two main Ca<sup>2+</sup> signaling enzymes that are most likely to be involved in ASD. On one hand the Ca<sup>2+</sup> and Calmodulin-binding pathways may be interesting targets for therapeutic interventions. However, future studies in mouse models, and electrophysiology studies in humans, are necessary to understand how and why the Ca<sup>2+</sup> signaling pathway is involved in ASD. Further studies are particularly needed to clarify the potential roles of Ca<sup>2+</sup> signaling in social behaviors or repetitive behaviors, which form the core features of ASD. </p>
</sec>
</sec>
<sec id="sec5-ijms-18-00828">
<title>5. Additional Signaling Pathways</title>
<p>Thus far, we have discussed the Wnt-signaling and Calmodulin-binding pathways as potential molecular mechanisms that are involved in ASD, due to the fact that these pathways have been found to be enriched for ASD-associated genes in multiple network-based analysis. In addition to these pathways, the mTOR-signaling and NGF-signaling pathways have also appeared in some of the discussed bioinformatic publications, although not quite as often as the Wnt and Calmodulin pathways. The mTOR pathway has already gained significant attention in connection to autism due to its significant involvement in syndromic autisms, as explained below. There is yet little known connection between NGF and ASD, however it is worth shortly considering the possible connections, considering its roles in brain development and function.</p>
<sec id="sec5dot1-ijms-18-00828">
<title>5.1. The PI3K/Mtor-Signaling Pathway</title>
<p>Mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase, which is considered a central kinase in organism development. Therefore it is of no surprise that ablation of mTOR results in in-utero death a short time after the implantation stage of the embryo in the uterus endometrium [<xref ref-type="bibr" rid="B104-ijms-18-00828">104</xref>]. The mTOR pathway regulates brain development through two main cascades driven by two complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). In the developing brain each cascade seems to take part in unique developmental duties [<xref ref-type="bibr" rid="B105-ijms-18-00828">105</xref>]. The mTORC2 cascade facilitates growth cone motility through its interaction with actin filaments. This role is essential for pathfinding dynamics of the neurite in the developing brain. Additionally, mTORC2 has an indirect influence on neuron size and morphology by regulating mTORC1 through RAC-alpha serine/threonine-protein kinase (AKT) activity. AKT activates mTORC1 which in turn phosphorylates p70 ribosomal protein S6 kinase (p70S6K) and eukaryotic Initiation Factor 4E (eIF4E)-binding protein (4EBP), which enhance a downstream cascade necessary for both protein synthesis and lipid synthesis. The products are used for plasma membrane expansion that is required for neurite elongation and arborization, and dendrite formation. This developmental mechanism driven by mTORC1 may also be directly activated by extracellular stimulation such as growth factors and neurotransmitters.</p>
<p>There is an abundance of publications linking mTOR-signaling to ASD, and it is considered to be one of the most promising converging signaling pathway candidates for ASD development. The involvement of mTOR-signaling in ASD and other neuropsychiatric conditions has been thoroughly reviewed previously [<xref ref-type="bibr" rid="B106-ijms-18-00828">106</xref>]. However, unlike the previously described pathways in this review, and to the best of our knowledge, only one publication has described a link between the mTOR-signaling pathway and ASD using a network analysis-based approach [<xref ref-type="bibr" rid="B38-ijms-18-00828">38</xref>]. Rather, the evidence for mTOR-signaling as a promising common ASD pathway candidate arise mostly from in vivo research into syndromic autisms such as Tuberous Sclerosis (TS), <italic>PTEN</italic>-related syndrome, Neurofibromatosis Type 1 (NF-1) and FXS [<xref ref-type="bibr" rid="B12-ijms-18-00828">12</xref>,<xref ref-type="bibr" rid="B107-ijms-18-00828">107</xref>,<xref ref-type="bibr" rid="B108-ijms-18-00828">108</xref>,<xref ref-type="bibr" rid="B109-ijms-18-00828">109</xref>]. In TS, the TSC1/2 complex has an inhibitory role on mTORC1, and knockdown of TSC2 results in over-activation of mTORC1 and mTORC2, leading to an increase in neuronal cell size of the fetal brain [<xref ref-type="bibr" rid="B110-ijms-18-00828">110</xref>]. Interestingly, blocking mTOR activity in TSC2-haploinsufficient mice using rapamycin reversed social deficits, suggesting that mTOR-signaling has a role in the manifestation of overall autistic behaviors, and in TSC particularly [<xref ref-type="bibr" rid="B111-ijms-18-00828">111</xref>]. PTEN is a phosphatase which also acts as a negative regulator of the mTOR-signaling pathway by reducing the activity of the PI3K/AKT pathway. As previously mentioned, AKT activates mTORC1 which is essential for protein synthesis of the developing neurite. Therefore, PTEN dysfunction might lead to increased protein synthesis and abnormal brain growth. Indeed, it has been shown that <italic>PTEN</italic> mutations in a subset of ASD cases are co-morbid with overgrowth and macrocephaly [<xref ref-type="bibr" rid="B112-ijms-18-00828">112</xref>]. Mouse models with conditional knockout of <italic>PTEN</italic> in mature neurons of the cerebral cortex and hippocampus display axonal overgrowth, ectopic axonal projections, and abnormal synapses, as well as reduced social interaction, increased anxiety, and hyperexcitability [<xref ref-type="bibr" rid="B113-ijms-18-00828">113</xref>]. In a recent publication by Cupolillo et al., conditional knockout of PTEN in cerebellar Purkinje cells led to a reduction in social interaction and repetitive behavior, paralleled with structural abnormalities in cerebellar axons and dendrites [<xref ref-type="bibr" rid="B114-ijms-18-00828">114</xref>]. Neurofibromin (NF), a tumor suppressor through its GTPase-activating function, is an additional negative regulator of mTOR-signaling via TSC2 [<xref ref-type="bibr" rid="B115-ijms-18-00828">115</xref>]. It is the key inducer of the familial cancer syndrome, NF-1, a pathology where autism-like social dysfunction has also been observed [<xref ref-type="bibr" rid="B108-ijms-18-00828">108</xref>]. It is still unclear exactly how NF is specifically involved with the ASD-like phenotype observed in NF-1. However, considering that the disequilibrium of the negative regulation of mTOR-signaling both by TSC1/2 and PTEN has been shown to be impaired in syndromic autisms, it is possible to claim that NF has a role in ASD-like phonotype development through its regulation of mTOR. In the case of FXS, increased phosphorylation of mTOR and p70S6K was observed both in lymphocytes and brain samples of FXS patients, which suggest increased protein synthesis, which is the main avenue by which mTOR dysregulation is believe to induce ASD development [<xref ref-type="bibr" rid="B109-ijms-18-00828">109</xref>].</p>
<p>In all of the examples given above, inability to downregulate mTOR-signaling is associated with the autism phenotype. In fact, studies determined that blocking mTOR through the use of Rapamycin improves social deficits in the TS and BTBR mouse models [<xref ref-type="bibr" rid="B111-ijms-18-00828">111</xref>,<xref ref-type="bibr" rid="B116-ijms-18-00828">116</xref>] which implies that Rapamycin might be a possible therapy for the social deficits in ASD.</p>
</sec>
<sec id="sec5dot2-ijms-18-00828">
<title>5.2. Nerve Growth Factor</title>
<p>Nerve Growth Factor (NGF) is a primary neurotrophin for peripheral organ innervation and sensory neuron development. As the nervous system develops, target-organs secret NGF that is detected by elongating axons, and through receptor-mediated endocytosis it enhances survival, neurite outgrowth and synaptic plasticity and connectivity [<xref ref-type="bibr" rid="B117-ijms-18-00828">117</xref>]. A role for NGF in the CNS was initially observed in the developing rat forebrain, as researchers injected exogenous NGF intraventricularly to neonatal rats, which resulted in an increase of Choline Acetyltransferase (ChAT) [<xref ref-type="bibr" rid="B118-ijms-18-00828">118</xref>]. Further studies of NGF in the rat forebrain showed that NGF regulates cholinergic development and differentiation by binding Tropomyosin receptor kinase A (TrkA), which by a positive feedback loop, increases TrkA expression as well as ChAT in cholinergic neurons [<xref ref-type="bibr" rid="B119-ijms-18-00828">119</xref>]. Since then, NGF, together with BDNF, have been shown to play an important role in orchestrating neuronal plasticity important for sociability in mice [<xref ref-type="bibr" rid="B117-ijms-18-00828">117</xref>]. </p>
<p>Given its important role in nervous system development, it is not surprising that dysregulation in NGF-signaling has been implicated in psychiatric disorders such as depression, schizophrenia and Alzheimer’s disease [<xref ref-type="bibr" rid="B117-ijms-18-00828">117</xref>]. Nevertheless, the number of publications linking NGF to ASD is scarce. In fact, some publications have shown that NGF levels in cerebral spinal fluid (CSF) and blood is typical in children with ASD [<xref ref-type="bibr" rid="B120-ijms-18-00828">120</xref>,<xref ref-type="bibr" rid="B121-ijms-18-00828">121</xref>]. However, more recent publications begin to present a different picture. A study analyzing Differential Alternative Splicing (DAS) in the blood mRNA of 2–4 year old boys diagnosed with ASD showed there was a significant difference in DAS for several genes involved in NGF-signaling, including the NGF receptors, Nerve Growth Factor Receptor (NGFR) and Neurotrophic Receptor Tyrosine Kinase 1 (NTRK1) [<xref ref-type="bibr" rid="B122-ijms-18-00828">122</xref>]. A different study showed that SNPs in NTRK1 associated with ASD behavioral traits measured by the Empathy Quotient (EQ) and the Autism Spectrum Quotient (AQ) [<xref ref-type="bibr" rid="B123-ijms-18-00828">123</xref>]. In an interesting study by Lu et al., researchers conducted a genome-wide Quantitative Trait Loci (QTL) study and found that several SNPs in NGF are significantly associated with deficits in non-verbal communication, which is an autistic trait [<xref ref-type="bibr" rid="B124-ijms-18-00828">124</xref>]. The reasoning for the QTL approach was to focus on a specific trait and find the genetic loci associated to it and reduce some of the genetic heterogeneity that usually complicates ASD genetic research. Therefore, while there is scarce evidence for the role of NGF-signaling in ASD from animal studies, human genetic studies have actually found associations between the NGF pathway and behaviors that are dysregulated in ASD. Therefore, further research into the possible mechanistic roles for NGF in social behavior are needed [<xref ref-type="bibr" rid="B39-ijms-18-00828">39</xref>].</p>
</sec>
</sec>
<sec id="sec6-ijms-18-00828">
<title>6. Conclusions</title>
<p>ASD’s elusive genetic etiology imposes a great challenge to our understanding of the disorder’s pathology. The growing number of genes associated with ASD, both rare and common variants, and the fact that these genes are involved in a variety of biological processes, makes it difficult for the research community to find a specific target for therapy. Taking into account that there are currently no pharmacological agents that treat the core symptoms of ASD, there is great need to understand the biological pathways that are targeted by ASD-mutations, which can be novel pharmacological targets. Both Wnt and the Ca<sup>2+</sup> signaling pathways that we discussed in-depth in this review are potential targets for pharmacological intervention. However, while these pathways have been well characterized, there is still a great need to understand exactly how dysregulation of these pathways are involved in the core characteristics of ASD, including social and repetitive behaviors. A more clear understanding of the specific roles of these pathways in specific brain region is also likely to shed some light into this issue.</p>
<p>Up until now, the only way to find common pathways affected by ASD-associated genes was by in-silico network analysis. However, with the creation of multiple mouse models based on these genetic aberrations, a current method can be to decipher common molecular dysregulations found in these multiple autism mouse models, and to correlate these dysregulations with the animal’s behavioral and neurodevelopmental phenotypes. For example, Ellegood et al. revealed that autism mouse models can be clustered according to neuroanatomical differences such as changes in the volume of different brain regions [<xref ref-type="bibr" rid="B125-ijms-18-00828">125</xref>]. In a recent review, Kim et al., compared publications on multiple mouse models, and searched for physiological dysregulations underlying the variety of repetitive behavior types observed in ASD mouse models. While Kim et al. deciphered that it is difficult to link repetitive behavior types to specific brain regions, they discovered a few common pathways that are often involved in ASD phenotypes [<xref ref-type="bibr" rid="B126-ijms-18-00828">126</xref>]. One example is involvement of glutamatergic connections from the frontal cortex to the midbrain, involved in repetitive behaviors. Therefore, the spatial and temporal resolution of ASD-related molecular pathways cannot be determined by network analysis of genetic data, but rather through the analysis of in vivo models. Therefore, parallel investigation of molecular mechanisms dysregulated in multiple mouse models of autism genes is likely to reveal important mechanisms and novel therapeutic targets.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>Our research is currently being supported by Israel Science Foundation grant 1047/12 and by a grant from Teva Pharmaceutical Industries.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>Both Oded Oron and Evan Elliott designed, wrote, and edited this review, according to own expertise. All authors have read and approved the final version of the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ADHD</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Attention Deficit Hyperactivity Disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AKT</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">RAC-alpha serine/threonine-protein kinase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AMPK</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">AMP-activated Protein Kinase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AQ</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Autism Spectrum Quotient </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AS</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Angelman Syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ASD</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Autism Spectrum Disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BDNF</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Brain-derived Neurotrophic Factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="bottom">BIO</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">(2′<italic>Z</italic>,3′<italic>E</italic>)-6-Bromoindirubin-3′-oxime</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CaM</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Calmodulin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CAMK</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Ca<sup>2+</sup>/calmodulin-dependent protein kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CASK</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Calcium/Calmodulin Dependent Serine Protein Kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CDFE</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Cortical Dysplasia-focal Epilepsy </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ChAT</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Choline Acetyltransferase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CHD8</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Chromodomain Helicase DNA Binding Protein 8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CNS</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Central Nervous System</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CNTNAP2</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Contacting Associated Protein 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CNV</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Copy Number Variation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">COL11A1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Collagen Type XI Alpha 1 Chain</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="bottom">DAS</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Differential Alternative Splicing </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Dlgap2</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">DLG Associated Protein 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Dvl3</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Dishevelled Segment Polarity Protein 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">eIF4E</td>
<td align="left" colspan="1" rowspan="1" valign="top">Eukaryotic Translation Initiation Factor 4E</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">EQ</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Empathy Quotient </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FMR1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Fragile-X Mental Retardation 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FNI</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Frizzled Nuclear Import </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FOXP1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Forkhead Box P1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FXS</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Fragile-X Syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Fzd1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Frizzled Class Receptor 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GABA</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Gamma-Aminobutyric </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GJB6</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Gap Junction Protein Beta 6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GOC</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Gene Ontology Consortium</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GRIN2B</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Glutamate Ionotropic Receptor NMDA Type Subunit 2B</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GSK3β</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Glycogen Synthase Kinase 3 Beta</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GWAS</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Genome Wide Association Study</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">H1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Homer 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">H2</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Homer 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Hipk1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Homeodomain Interacting Protein Kinase 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ID</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Intellectual Deficiency</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">IPA</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Ingenuity Pathway Analysis </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">iPSC</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">induced pluripotent stem cells</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">KATNAL2</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Katanin Catalytic Subunit A1 Like 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">KCNQ4</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Potassium Voltage-Gated Channel Subfamily Q Member 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">KEGG</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Kyoto Encyclopedia of Genes and Genomes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LAMC3</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Laminin Subunit Gamma 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LEF</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Lymphoid Enhancer Binding Factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LRP5</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">LDL Receptor Related Protein 5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LRP6</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">LDL Receptor Related Protein 6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LTP</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Long Term Potentiation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MECP2</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Methyl CpG binding protein 2 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="bottom">mGluR5</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Glutamate Metabotropic Receptor 5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">mTOR</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Mammalian Target of Rapamycin </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">mTORC1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Mammalian Target of Rapamycin complex 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">mTORC2</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Mammalian Target of Rapamycin complex 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MYH14</td>
<td align="left" colspan="1" rowspan="1" valign="top">Myosin Heavy Chain 14</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="bottom">NF</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Neurofibromin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NF-1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Neurofibromatosis Type 1 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NGF</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Nerve Growth Factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NGFR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nerve Growth Factor Receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NGS</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Next Generations Sequencing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NMDAR</td>
<td align="left" colspan="1" rowspan="1" valign="bottom"><italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NSC</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Neuronal Stem Cell </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NTNG1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Netrin G1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NTRK1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Neurotrophic Receptor Tyrosine Kinase 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">p70S6K</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">p70 ribosomal protein S6 kinase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PI3K</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Phosphatidylinositol-4,5-Bisphosphate 3-Kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PPI</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Protein-Protein Interaction</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="bottom">PROSAP2</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Proline Rich Synapse Associated Protein 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PSD</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Post Synaptic Density</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PTEN</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Phosphatase And Tensin Homolog</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PV</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Parvalbumin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PVD</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Pial Vessel Disruption</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">QTL</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Quantitative Trait Loci </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SCN1A</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Sodium Voltage-Gated Channel Alpha Subunit 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SCN2A</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Sodium Voltage-Gated Channel Alpha Subunit 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SFARI</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Simmons Foundation Autism Research Initiative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SHANK3</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">SH3 And Multiple Ankyrin Repeat Domains 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SNP</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Single Nucleotide Polymorphism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">STXBP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Syntaxin Binding Protein 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SVZ</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Subventricular Zone</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Syngap1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Synaptic Ras GTPase Activating Protein 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TCF</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Transcription Factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">THRA</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Thyroid Hormone Receptor, Alpha</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TMS</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Transcranial Magnetic Stimulation </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TrkA</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Tropomyosin receptor kinase A </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TSC1</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Tuberous Sclerosis 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TSC2</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Tuberous Sclerosis 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">UBE3A</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Ubiquitin Protein Ligase E3A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">WGCNA</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Weighted Gene Co-expression Network Analysis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Wnt</td>
<td align="left" colspan="1" rowspan="1" valign="bottom">Wingless-type</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-18-00828">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grice</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Buxbaum</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>The Genetics of Autism Spectrum Disorders</article-title>
<source/>NeuroMol. Med.
          <year>2006</year>
<volume>8</volume>
<fpage>451</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="doi">10.1385/NMM:8:4:451</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-18-00828">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folstein</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Infantile autism: A genetic study of 21 twin pairs</article-title>
<source/>J. Child Psychol. Psychiatry
          <year>1977</year>
<volume>18</volume>
<fpage>297</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-7610.1977.tb00443.x</pub-id>
<pub-id pub-id-type="pmid">562353</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-18-00828">
<label>3.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Folstein</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>A Twin Study of Individuals with Infantile Autism</article-title>
<source/>Autism: A Reappraisal of Concepts and Treatment
          <person-group person-group-type="editor">
<name>
<surname>Rutter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schopler</surname>
<given-names>E.</given-names>
</name>
</person-group>
<publisher-name>Springer</publisher-name>
<publisher-loc>Boston, MA, USA</publisher-loc>
<year>1978</year>
<fpage>219</fpage>
<lpage>241</lpage>
</element-citation>
</ref>
<ref id="B4-ijms-18-00828">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rutter</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Heritability of autism spectrum disorders: A meta-analysis of twin studies</article-title>
<source/>J. Child Psychol. Psychiatry
          <year>2016</year>
<volume>57</volume>
<fpage>585</fpage>
<lpage>595</lpage>
<pub-id pub-id-type="pmid">26709141</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-18-00828">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taurines</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schwenck</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Westerwald</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sachse</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Siniatchkin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Freitag</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>ADHD and autism: Differential diagnosis or overlapping traits? A selective review</article-title>
<source/>Atten. Defict Hyperact. Disord.
          <year>2012</year>
<volume>4</volume>
<fpage>115</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1007/s12402-012-0086-2</pub-id>
<pub-id pub-id-type="pmid">22851255</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-18-00828">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollocks</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Howlin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Papadopoulos</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Khondoker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Simonoff</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Differences in HPA-axis and heart rate responsiveness to psychosocial stress in children with autism spectrum disorders with and without co-morbid anxiety</article-title>
<source/>Psychoneuroendocrinology
          <year>2014</year>
<volume>46</volume>
<fpage>32</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2014.04.004</pub-id>
<pub-id pub-id-type="pmid">24882156</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-18-00828">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Talkowski</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Mullegama</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Van Bon</surname>
<given-names>B.W.M.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Repnikova</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Gastier-Foster</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thrush</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Kathiresan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ruderfer</surname>
<given-names>D.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder</article-title>
<source/>Am. J. Hum. Genet.
          <year>2011</year>
<volume>89</volume>
<fpage>551</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2011.09.011</pub-id>
<pub-id pub-id-type="pmid">21981781</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-18-00828">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khanzada</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Manzardo</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>GeneAnalytics Pathway Analysis and Genetic Overlap among Autism Spectrum Disorder, Bipolar Disorder and Schizophrenia</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<volume>18</volume>
<fpage>527</fpage>
<pub-id pub-id-type="doi">10.3390/ijms18030527</pub-id>
<pub-id pub-id-type="pmid">28264500</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-18-00828">
<label>9.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Buxbaum</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Hof</surname>
<given-names>P.R.</given-names>
</name>
</person-group>
<source/>The Neuroscience of Autism Spectrum Disorders
          <publisher-name>Elsevier Science</publisher-name>
<publisher-loc>Amsterdam, The Netherlands</publisher-loc>
<year>2012</year>
</element-citation>
</ref>
<ref id="B10-ijms-18-00828">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hoem</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Fragile X and autism: Intertwined at the molecular level leading to targeted treatments</article-title>
<source/>Mol. Autism
          <year>2010</year>
<volume>1</volume>
<fpage>12</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-1-12</pub-id>
<pub-id pub-id-type="pmid">20858229</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-18-00828">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strauss</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Puffenberger</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Huentelman</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dobrin</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Parod</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Stephan</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2</article-title>
<source/>N. Engl. J. Med.
          <year>2006</year>
<volume>354</volume>
<fpage>1370</fpage>
<lpage>1377</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa052773</pub-id>
<pub-id pub-id-type="pmid">16571880</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-18-00828">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vignoli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>La Briola</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Peron</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vannicola</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Saccani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Magnaghi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Scornavacca</surname>
<given-names>G.F.</given-names>
</name>
<name>
<surname>Canevini</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorder in tuberous sclerosis complex: Searching for risk markers</article-title>
<source/>Orphanet J. Rare Dis.
          <year>2015</year>
<volume>10</volume>
<fpage>154</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-015-0371-1</pub-id>
<pub-id pub-id-type="pmid">26631248</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-18-00828">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Percy</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>Rett syndrome: Exploring the autism link</article-title>
<source/>Arch. Neurol.
          <year>2011</year>
<volume>68</volume>
<fpage>985</fpage>
<lpage>989</lpage>
<pub-id pub-id-type="doi">10.1001/archneurol.2011.149</pub-id>
<pub-id pub-id-type="pmid">21825235</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-18-00828">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leppa</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Kravitz</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Andrieux</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Le Caignec</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Martin-Coignard</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>DyBuncio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Cantor</surname>
<given-names>R.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare Inherited and De Novo CNVs Reveal Complex Contributions to ASD Risk in Multiplex Families</article-title>
<source/>Am. J. Hum. Genet.
          <year>2016</year>
<volume>99</volume>
<fpage>540</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.06.036</pub-id>
<pub-id pub-id-type="pmid">27569545</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-18-00828">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>H.L.</given-names>
</name>
</person-group>
<article-title>Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms</article-title>
<source/>J. Med. Genet.
          <year>2003</year>
<volume>40</volume>
<fpage>575</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.40.8.575</pub-id>
<pub-id pub-id-type="pmid">12920066</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-18-00828">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durand</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Betancur</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Boeckers</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Bockmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chaste</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fauchereau</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nygren</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rastam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Anckarsäter</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders</article-title>
<source/>Nat. Genet.
          <year>2007</year>
<volume>39</volume>
<fpage>25</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1038/ng1933</pub-id>
<pub-id pub-id-type="pmid">17173049</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-18-00828">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Bey</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.-H.</given-names>
</name>
</person-group>
<article-title>Transcriptional and functional complexity of SHANK3 provides a molecular framework to understand the phenotypic heterogeneity of SHANK3 causing autism and SHANK3 mutant mice</article-title>
<source/>Mol. Autism
          <year>2014</year>
<volume>5</volume>
<fpage>30</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-5-30</pub-id>
<pub-id pub-id-type="pmid">25071925</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-18-00828">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ornoy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liza</surname>
<given-names>W.F.</given-names>
</name>
<name>
<surname>Ergaz</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Genetic syndromes, maternal diseases and antenatal factors associated with autism spectrum disorders (ASD)</article-title>
<source/>Front. Neurosci.
          <year>2016</year>
<volume>10</volume>
<fpage>1</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00316</pub-id>
<pub-id pub-id-type="pmid">26858586</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-18-00828">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Anda</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Rosario</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Durak</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gräff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meletis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rei</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Soda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Madabhushi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ginty</surname>
<given-names>D.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism spectrum disorder susceptibility gene TAOK2 affects basal dendrite formation in the neocortex</article-title>
<source/>Nat. Neurosci.
          <year>2012</year>
<volume>15</volume>
<fpage>1022</fpage>
<lpage>1031</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3141</pub-id>
<pub-id pub-id-type="pmid">22683681</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-18-00828">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golzio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Willer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Talkowski</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Reymond</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gusella</surname>
<given-names>J.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<fpage>363</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="doi">10.1038/nature11091</pub-id>
<pub-id pub-id-type="pmid">22596160</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-18-00828">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Roak</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Deriziotis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karakoc</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing in spordic autism spectrum disorders identifies severe de novo mutations</article-title>
<source/>Nat. Genet.
          <year>2011</year>
<volume>43</volume>
<fpage>585</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="doi">10.1038/ng.835</pub-id>
<pub-id pub-id-type="pmid">21572417</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-18-00828">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ronemus</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hakker</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rosenbaum</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yamrom</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Narzisi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Leotta</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De Novo Gene Disruptions in Children on the Autistic Spectrum</article-title>
<source/>Neuron
          <year>2012</year>
<volume>74</volume>
<fpage>285</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.04.009</pub-id>
<pub-id pub-id-type="pmid">22542183</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-18-00828">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Roak</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karakoc</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Krumm</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<fpage>246</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1038/nature10989</pub-id>
<pub-id pub-id-type="pmid">22495309</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-18-00828">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Murtha</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Murdoch</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Raubeson</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Willsey</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Ercan-Sencicek</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>DiLullo</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Parikshak</surname>
<given-names>N.N.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>J.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations revealed by whole-exome sequencing are strongly associated with autism</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<fpage>237</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1038/nature10945</pub-id>
<pub-id pub-id-type="pmid">22495306</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-18-00828">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuen</surname>
<given-names>R.K.C.</given-names>
</name>
<name>
<surname>Thiruvahindrapuram</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tammimies</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hoang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chrysler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nalpathamkalam</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pellecchia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole-genome sequencing of quartet families with autism spectrum disorder</article-title>
<source/>Nat. Med.
          <year>2015</year>
<volume>21</volume>
<fpage>185</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1038/nm.3792</pub-id>
<pub-id pub-id-type="pmid">25621899</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-18-00828">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaugler</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Klei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Bodea</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Mahajan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Manaa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pawitan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Reichert</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Most genetic risk for autism resides with common variation</article-title>
<source/>Nat. Genet.
          <year>2014</year>
<volume>46</volume>
<fpage>881</fpage>
<lpage>885</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3039</pub-id>
<pub-id pub-id-type="pmid">25038753</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-18-00828">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basu</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Kollu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Banerjee-Basu</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>AutDB: A gene reference resource for autism research</article-title>
<source/>Nucleic Acids Res.
          <year>2009</year>
<volume>37</volume>
<fpage>D832</fpage>
<lpage>D836</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkn835</pub-id>
<pub-id pub-id-type="pmid">19015121</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-18-00828">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Autism: Many genes, common pathways?</article-title>
<source/>Cell
          <year>2008</year>
<volume>135</volume>
<fpage>391</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.10.016</pub-id>
<pub-id pub-id-type="pmid">18984147</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-18-00828">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parikshak</surname>
<given-names>N.N.</given-names>
</name>
<name>
<surname>Gandal</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders</article-title>
<source/>Nat. Rev. Genet.
          <year>2015</year>
<volume>16</volume>
<fpage>441</fpage>
<lpage>458</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3934</pub-id>
<pub-id pub-id-type="pmid">26149713</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-18-00828">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>The Gene Ontology Consortium</collab>
<name>
<surname>Ashburner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Blake</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Botstein</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Michael Cherry</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Dolinski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dwight</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Eppig</surname>
<given-names>J.T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene Ontology: Tool for the unification of biology</article-title>
<source/>Nat. Genet.
          <year>2000</year>
<volume>25</volume>
<fpage>25</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">10802651</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-18-00828">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chowdhury</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>R.R.</given-names>
</name>
</person-group>
<article-title>Comparison of human cell signaling pathway databases—Evolution, drawbacks and challenges</article-title>
<source/>Database
          <year>2015</year>
<volume>2015</volume>
<pub-id pub-id-type="doi">10.1093/database/bau126</pub-id>
<pub-id pub-id-type="pmid">25632107</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-18-00828">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Goto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fujibuchi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bono</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kanehisa</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>KEGG: Kyoto Encyclopedia of Genes and Genomes</article-title>
<source/>Nucleic Acids Res.
          <year>1999</year>
<volume>27</volume>
<fpage>29</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1093/nar/27.1.29</pub-id>
<pub-id pub-id-type="pmid">9847135</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-18-00828">
<label>33.</label>
<element-citation publication-type="web">
<article-title>Ingenuity Systems Ingenuity Pathway Analysis (IPA)</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.qiagenbioinformatics.com/">https://www.qiagenbioinformatics.com/</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2017-04-13">(accessed on 13 April 2017)</date-in-citation>
</element-citation>
</ref>
<ref id="B34-ijms-18-00828">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mines</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Yuskaitis</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Beurel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jope</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>GSK3 Influences Social Preference and Anxiety-Related Behaviors during Social Interaction in a Mouse Model of Fragile X Syndrome and Autism</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e9706</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0009706</pub-id>
<pub-id pub-id-type="pmid">20300527</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-18-00828">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okerlund</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Cheyette</surname>
<given-names>B.N.R.</given-names>
</name>
</person-group>
<article-title>Synaptic Wnt signaling—A contributor to major psychiatric disorders?</article-title>
<source/>J. Neurodev. Disord.
          <year>2011</year>
<volume>3</volume>
<fpage>162</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1007/s11689-011-9083-6</pub-id>
<pub-id pub-id-type="pmid">21533542</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-18-00828">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>O’roak</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Ronemus</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Krumm</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stessman</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Witherspoon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>K.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The contribution of de novo coding mutations to autism spectrum disorder</article-title>
<source/>November
          <year>2014</year>
<volume>13</volume>
<fpage>216</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/nature13908</pub-id>
<pub-id pub-id-type="pmid">25363768</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-18-00828">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hadley</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.-L.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohamed-Hadley</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vazquez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mentch</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pellegrino</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism</article-title>
<source/>Nat. Commun.
          <year>2014</year>
<volume>5</volume>
<pub-id pub-id-type="doi">10.1038/ncomms5074</pub-id>
<pub-id pub-id-type="pmid">24927284</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-18-00828">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Alshikho</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Herbert</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Pathway network analyses for autism reveal multisystem involvement, major overlaps with other diseases and convergence upon MAPK and Calcium signaling</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0153329</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0153329</pub-id>
<pub-id pub-id-type="pmid">27055244</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-18-00828">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Corominas</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lemmens</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tavernier</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Vidal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sebat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Iakoucheva</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Spatiotemporal 16p11.2 Protein Network Implicates Cortical Late Mid-Fetal Brain Development and KCTD13-Cul3-RhoA Pathway in Psychiatric Diseases</article-title>
<source/>Neuron
          <year>2015</year>
<volume>85</volume>
<fpage>742</fpage>
<lpage>754</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2015.01.010</pub-id>
<pub-id pub-id-type="pmid">25695269</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-18-00828">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben-David</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shifman</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Networks of neuronal genes affected by common and rare variants in autism spectrum disorders</article-title>
<source/>PLoS Genet.
          <year>2012</year>
<volume>8</volume>
<elocation-id>e1002556</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1002556</pub-id>
<pub-id pub-id-type="pmid">22412387</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-18-00828">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacDonald</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Tamai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases</article-title>
<source/>Dev. Cell
          <year>2009</year>
<volume>17</volume>
<fpage>9</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1016/j.devcel.2009.06.016</pub-id>
<pub-id pub-id-type="pmid">19619488</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-18-00828">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polakis</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Wnt signaling and cancer</article-title>
<source/>Genes Dev.
          <year>2000</year>
<volume>14</volume>
<fpage>1837</fpage>
<lpage>1851</lpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a008052</pub-id>
<pub-id pub-id-type="pmid">10921899</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-18-00828">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Kühl</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>An updated overview on Wnt signaling pathways: A prelude for more</article-title>
<source/>Circ. Res.
          <year>2010</year>
<volume>106</volume>
<fpage>1798</fpage>
<lpage>1806</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.219840</pub-id>
<pub-id pub-id-type="pmid">20576942</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-18-00828">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noelanders</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vleminckx</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>How Wnt Signaling Builds the Brain</article-title>
<source/>Neuroscientist
          <year>2016</year>
<pub-id pub-id-type="doi">10.1177/1073858416667270</pub-id>
<pub-id pub-id-type="pmid">27624848</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-18-00828">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Regulation of Cerebral Cortical Size by Control of Cell Cycle Exit in Neural Precursors</article-title>
<source/>Science
          <year>2002</year>
<volume>297</volume>
<fpage>365</fpage>
<lpage>369</lpage>
<pub-id pub-id-type="doi">10.1126/science.1074192</pub-id>
<pub-id pub-id-type="pmid">12130776</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-18-00828">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woodhead</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Mutch</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Chenn</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Cell-Autonomous beta-Catenin Signaling Regulates Cortical Precursor Proliferation</article-title>
<source/>J. Neurosci.
          <year>2006</year>
<volume>26</volume>
<fpage>12620</fpage>
<lpage>12630</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3180-06.2006</pub-id>
<pub-id pub-id-type="pmid">17135424</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-18-00828">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duncan</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Taibi</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Bonkowsky</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Douglass</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Dorsky</surname>
<given-names>R.I.</given-names>
</name>
</person-group>
<article-title>Hypothalamic radial glia function as self-renewing neural progenitors in the absence of Wnt/β-catenin signaling</article-title>
<source/>Development
          <year>2015</year>
<volume>143</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1242/dev.126813</pub-id>
<pub-id pub-id-type="pmid">26603385</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-18-00828">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piccin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Morshead</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Wnt signaling regulates symmetry of division of neural stem cells in the adult brain and in response to injury</article-title>
<source/>Stem Cells
          <year>2011</year>
<volume>29</volume>
<fpage>528</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1002/stem.589</pub-id>
<pub-id pub-id-type="pmid">21425415</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-18-00828">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marinaro</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pannese</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weinandy</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sessa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bergamaschi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Taketo</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Broccoli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Comi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Götz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martino</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wnt signaling has opposing roles in the developing and the adult brain that are modulated by Hipk1</article-title>
<source/>Cereb. Cortex
          <year>2012</year>
<volume>22</volume>
<fpage>2415</fpage>
<lpage>2427</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhr320</pub-id>
<pub-id pub-id-type="pmid">22095214</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-18-00828">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Krohn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kemler</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>A specific domain in alpha-catenin mediates binding to beta-catenin or plakoglobin</article-title>
<source/>J. Cell Sci.
          <year>1997</year>
<volume>110</volume>
<issue>Pt 1</issue>
<fpage>1759</fpage>
<lpage>1765</lpage>
<pub-id pub-id-type="pmid">9264463</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-18-00828">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Weis</surname>
<given-names>W.I.</given-names>
</name>
</person-group>
<article-title>The structure of the B-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by β-catenin</article-title>
<source/>Cell
          <year>2001</year>
<volume>105</volume>
<fpage>391</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(01)00330-0</pub-id>
<pub-id pub-id-type="pmid">11348595</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-18-00828">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Malenka</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>Beta-catenin is critical for dendritic morphogenesis</article-title>
<source/>Nat. Neurosci.
          <year>2003</year>
<volume>6</volume>
<fpage>1169</fpage>
<lpage>1177</lpage>
<pub-id pub-id-type="doi">10.1038/nn1132</pub-id>
<pub-id pub-id-type="pmid">14528308</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-18-00828">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bian</surname>
<given-names>W.-J.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>W.-Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.-J.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Coordinated Spine Pruning and Maturation Mediated by Inter-Spine Competition for Cadherin/Catenin Complexes</article-title>
<source/>Cell
          <year>2015</year>
<volume>162</volume>
<fpage>808</fpage>
<lpage>822</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.07.018</pub-id>
<pub-id pub-id-type="pmid">26255771</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-18-00828">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murase</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mosser</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Schuman</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Depolarization drives β-catenin into neuronal spines promoting changes in synaptic structure and function</article-title>
<source/>Neuron
          <year>2002</year>
<volume>35</volume>
<fpage>91</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(02)00764-X</pub-id>
<pub-id pub-id-type="pmid">12123611</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-18-00828">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Quantitative Analysis of Cadherin-Catenin-Actin Reorganization during Development of Cell-Cell Adhesion</article-title>
<source/>J. Cell Biol.
          <year>1996</year>
<volume>135</volume>
<fpage>1899</fpage>
<lpage>1911</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.135.6.1899</pub-id>
<pub-id pub-id-type="pmid">8991100</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-18-00828">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bamji</surname>
<given-names>S.X.</given-names>
</name>
<name>
<surname>Shimazu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kimes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Huelsken</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Birchmeier</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Reichardt</surname>
<given-names>L.F.</given-names>
</name>
</person-group>
<article-title>Role of β-catenin in synaptic vesicle localization and presynaptic assembly</article-title>
<source/>Neuron
          <year>2003</year>
<volume>40</volume>
<fpage>719</fpage>
<lpage>731</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(03)00718-9</pub-id>
<pub-id pub-id-type="pmid">14622577</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-18-00828">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>T.C.</given-names>
</name>
</person-group>
<article-title>A Tripartite Protein Complex with the Potential to Couple Synaptic Vesicle Exocytosis to Cell Adhesion in Brain</article-title>
<source/>Cell
          <year>1998</year>
<volume>94</volume>
<fpage>773</fpage>
<lpage>782</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81736-5</pub-id>
<pub-id pub-id-type="pmid">9753324</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-18-00828">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Malintan</surname>
<given-names>N.T.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Meunier</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Sugita</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Munc18-1 as a key regulator of neurosecretion</article-title>
<source/>J. Neurochem.
          <year>2010</year>
<volume>115</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06900.x</pub-id>
<pub-id pub-id-type="pmid">20681955</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-18-00828">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolshakov</surname>
<given-names>V.Y.</given-names>
</name>
<name>
<surname>Siegelbaum</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Regulation of hippocampal transmitter release during development and long-term potentiation</article-title>
<source/>Science
          <year>1995</year>
<volume>269</volume>
<fpage>1730</fpage>
<lpage>1734</lpage>
<pub-id pub-id-type="doi">10.1126/science.7569903</pub-id>
<pub-id pub-id-type="pmid">7569903</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-18-00828">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Schuman</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Axonal translation of beta-catenin regulates synaptic vesicle dynamics</article-title>
<source/>J. Neurosci.
          <year>2013</year>
<volume>33</volume>
<fpage>5584</fpage>
<lpage>5589</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2944-12.2013</pub-id>
<pub-id pub-id-type="pmid">23536073</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-18-00828">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nieland</surname>
<given-names>T.J.F.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huganir</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>High-throughput genetic screen for synaptogenic factors: Identification of LRP6 as critical for excitatory synapse development</article-title>
<source/>Cell Rep.
          <year>2013</year>
<volume>5</volume>
<fpage>1330</fpage>
<lpage>1341</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2013.11.008</pub-id>
<pub-id pub-id-type="pmid">24316074</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-18-00828">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hutsler</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders</article-title>
<source/>Brain Res.
          <year>2010</year>
<volume>1309</volume>
<fpage>83</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2009.09.120</pub-id>
<pub-id pub-id-type="pmid">19896929</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-18-00828">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Sunkin</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Mouton</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wynshaw-Boris</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Colamarino</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Lein</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Courchesne</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Patches of disorganization in the neocortex of children with autism</article-title>
<source/>N. Engl. J. Med.
          <year>2014</year>
<volume>370</volume>
<fpage>1209</fpage>
<lpage>1219</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1307491</pub-id>
<pub-id pub-id-type="pmid">24670167</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-18-00828">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casanova</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>van Kooten</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Switala</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>van Engeland</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Heinsen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Steinbusch</surname>
<given-names>H.W.M.</given-names>
</name>
<name>
<surname>Hof</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Abnormalities of cortical minicolumnar organization in the prefrontal lobes of autistic patients</article-title>
<source/>Clin. Neurosci. Res.
          <year>2006</year>
<volume>6</volume>
<fpage>127</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1016/j.cnr.2006.06.003</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-18-00828">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Kalyanasundaram</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Andalman</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Mirzabekov</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Zalocusky</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Mattis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Denisin</surname>
<given-names>A.K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structural and molecular interrogation of intact biological systems</article-title>
<source/>Nature
          <year>2013</year>
<volume>497</volume>
<fpage>332</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1038/nature12107</pub-id>
<pub-id pub-id-type="pmid">23575631</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-18-00828">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McSweeney</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Deletion of CTNNB1 in inhibitory circuitry contributes to autism-associated behavioral defects</article-title>
<source/>Hum. Mol. Genet.
          <year>2016</year>
<volume>25</volume>
<fpage>2738</fpage>
<lpage>2751</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddw131</pub-id>
<pub-id pub-id-type="pmid">27131348</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-18-00828">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mines</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Jope</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Glycogen synthase kinase-3: A promising therapeutic target for fragile X syndrome</article-title>
<source/>Front. Mol. Neurosci.
          <year>2011</year>
<volume>4</volume>
<fpage>35</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2011.00035</pub-id>
<pub-id pub-id-type="pmid">22053151</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-18-00828">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caracci</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Avila</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>de Ferrari</surname>
<given-names>G.V.</given-names>
</name>
</person-group>
<article-title>Synaptic Wnt/GSK3β-Signaling Hub in Autism</article-title>
<source/>Neural Plast.
          <year>2016</year>
<volume>2016</volume>
<pub-id pub-id-type="doi">10.1155/2016/9603751</pub-id>
<pub-id pub-id-type="pmid">26881141</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-18-00828">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Min</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Yuskaitis</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sikorski</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jope</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Bauchwitz</surname>
<given-names>R.P.</given-names>
</name>
</person-group>
<article-title>Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potential</article-title>
<source/>Neuropharmacology
          <year>2009</year>
<volume>56</volume>
<fpage>463</fpage>
<lpage>472</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.09.017</pub-id>
<pub-id pub-id-type="pmid">18952114</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-18-00828">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Murthy</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Schaller</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Allan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Inhibition of GSK3β improves hippocampusdependent learning and rescues neurogenesis in a mouse model of fragile X syndrome</article-title>
<source/>Hum. Mol. Genet.
          <year>2012</year>
<volume>21</volume>
<fpage>681</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr501</pub-id>
<pub-id pub-id-type="pmid">22048960</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-18-00828">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franklin</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Palomo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mcmahon</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Jope</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Glycogen synthase kinase-3 inhibitors reverse deficits in long- term potentiation and cognition in Fragile X mice</article-title>
<source/>Biol. Psychiatry
          <year>2014</year>
<volume>75</volume>
<fpage>198</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.08.003</pub-id>
<pub-id pub-id-type="pmid">24041505</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-18-00828">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durak</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kaeser-Woo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rueda</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Martorell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nott</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>L.-H.</given-names>
</name>
</person-group>
<article-title>Chd8 mediates cortical neurogenesis via transcriptional regulation of cell cycle and Wnt signaling</article-title>
<source/>Nat. Neurosci.
          <year>2016</year>
<volume>19</volume>
<fpage>1477</fpage>
<lpage>1488</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4400</pub-id>
<pub-id pub-id-type="pmid">27694995</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-18-00828">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Akbergenova</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Baas-Thomas</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Littleton</surname>
<given-names>J.T.</given-names>
</name>
</person-group>
<article-title>Shank Modulates Postsynaptic Wnt Signaling to Regulate Synaptic Development</article-title>
<source/>J. Neurosci.
          <year>2016</year>
<volume>36</volume>
<fpage>5820</fpage>
<lpage>5832</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4279-15.2016</pub-id>
<pub-id pub-id-type="pmid">27225771</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-18-00828">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Budnik</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Salinas</surname>
<given-names>P.C.</given-names>
</name>
</person-group>
<article-title>Wnt signaling during synaptic development and plasticity</article-title>
<source/>Curr. Opin. Neurobiol.
          <year>2011</year>
<volume>21</volume>
<fpage>151</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2010.12.002</pub-id>
<pub-id pub-id-type="pmid">21239163</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-18-00828">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathew</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ataman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cumberledge</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Budnik</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Wingless Signaling at Synapses Is through Cleavage and Nuclear Import of Receptor DFrizzled2</article-title>
<source/>Science
          <year>2005</year>
<volume>310</volume>
<fpage>1344</fpage>
<lpage>1347</lpage>
<pub-id pub-id-type="doi">10.1126/science.1117051</pub-id>
<pub-id pub-id-type="pmid">16311339</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-18-00828">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carafoli</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Special issue: Calcium signaling and disease</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2004</year>
<volume>322</volume>
<fpage>1097</fpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2004.08.049</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-18-00828">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berridge</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Lipp</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bootman</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>The versatility and universality of Calcium signalling</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2000</year>
<volume>1</volume>
<fpage>11</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1038/35036035</pub-id>
<pub-id pub-id-type="pmid">11413485</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-18-00828">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clapham</surname>
<given-names>D.E.</given-names>
</name>
</person-group>
<article-title>Calcium Signaling</article-title>
<source/>Cell
          <year>2007</year>
<volume>131</volume>
<fpage>1047</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.11.028</pub-id>
<pub-id pub-id-type="pmid">18083096</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-18-00828">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bossuyt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bers</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Visualizing CaMKII and CaM activity: A paradigm of compartmentalized signaling</article-title>
<source/>J. Mol. Med.
          <year>2013</year>
<volume>91</volume>
<fpage>907</fpage>
<lpage>916</lpage>
<pub-id pub-id-type="doi">10.1007/s00109-013-1060-y</pub-id>
<pub-id pub-id-type="pmid">23775230</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-18-00828">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamoto</surname>
<given-names>K.-I.</given-names>
</name>
<name>
<surname>Narayanan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The role of CaMKII as an F-actin-bundling protein crucial for maintenance of dendritic spine structure</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2007</year>
<volume>104</volume>
<fpage>6418</fpage>
<lpage>6423</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0701656104</pub-id>
<pub-id pub-id-type="pmid">17404223</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-18-00828">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jalan-Sakrikar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Baucum</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Colbran</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Substrate-selective and calcium-independent activation of CaMKII by α-actinin</article-title>
<source/>J. Biol. Chem.
          <year>2012</year>
<volume>287</volume>
<fpage>15275</fpage>
<lpage>15283</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.351817</pub-id>
<pub-id pub-id-type="pmid">22427672</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-18-00828">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hell</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>CaMKII: Claiming center stage in postsynaptic function and organization</article-title>
<source/>Neuron
          <year>2014</year>
<volume>81</volume>
<fpage>249</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2013.12.024</pub-id>
<pub-id pub-id-type="pmid">24462093</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-18-00828">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schulman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cline</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The molecular basis of CaMKII function in synaptic and behavioural memory</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2002</year>
<volume>3</volume>
<fpage>175</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1038/nrn753</pub-id>
<pub-id pub-id-type="pmid">11994750</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-18-00828">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houston</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Smart</surname>
<given-names>T.G.</given-names>
</name>
</person-group>
<article-title>CaMKII phosphorylation of the GABA A receptor: Receptor subtype-and synapse-specific modulation</article-title>
<source/>J. Physiol.
          <year>2009</year>
<volume>58710</volume>
<fpage>2115</fpage>
<lpage>2125</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.2009.171603</pub-id>
<pub-id pub-id-type="pmid">19332484</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-18-00828">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wayman</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Kaech</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>W.F.</given-names>
</name>
<name>
<surname>Davare</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Impey</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tokumitsu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nozaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Banker</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Soderling</surname>
<given-names>T.R.</given-names>
</name>
</person-group>
<article-title>Regulation of axonal extension and growth cone motility by calmodulin-dependent protein kinase I</article-title>
<source/>J. Neurosci.
          <year>2004</year>
<volume>24</volume>
<fpage>3786</fpage>
<lpage>3794</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3294-03.2004</pub-id>
<pub-id pub-id-type="pmid">15084659</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-18-00828">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizuno</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ris</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sánchez-Capelo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Godaux</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Giese</surname>
<given-names>K.P.</given-names>
</name>
</person-group>
<article-title>Ca<sup>2+</sup>/calmodulin kinase kinase alpha is dispensable for brain development but is required for distinct memories in male, though not in female, mice</article-title>
<source/>Mol. Cell. Biol.
          <year>2006</year>
<volume>26</volume>
<fpage>9094</fpage>
<lpage>9104</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01221-06</pub-id>
<pub-id pub-id-type="pmid">17015468</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-18-00828">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marcelo</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Means</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>York</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>The Ca<sup>2+</sup>/Calmodulin/CaMKK2 Axis: Nature’s Metabolic CaMshaft</article-title>
<source/>Trends Endocrinol. Metab.
          <year>2016</year>
<volume>27</volume>
<fpage>706</fpage>
<lpage>718</lpage>
<pub-id pub-id-type="doi">10.1016/j.tem.2016.06.001</pub-id>
<pub-id pub-id-type="pmid">27449752</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-18-00828">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yun</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Trommer</surname>
<given-names>B.L.</given-names>
</name>
</person-group>
<article-title>Fragile X mice: Reduced long-term potentiation and <italic>N</italic>-Methyl-<sc>d</sc>-Aspartate receptor-mediated neurotransmission in dentate gyrus</article-title>
<source/>J. Neurosci. Res.
          <year>2011</year>
<volume>89</volume>
<fpage>176</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.22546</pub-id>
<pub-id pub-id-type="pmid">21162125</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-18-00828">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Levenson</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Atkinson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Teague</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Antalffy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Arancio</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Sweatt</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome</article-title>
<source/>J. Neurosci.
          <year>2006</year>
<volume>26</volume>
<fpage>319</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2623-05.2006</pub-id>
<pub-id pub-id-type="pmid">16399702</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-18-00828">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>N.H.</given-names>
</name>
<name>
<surname>Janzarik</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Delvendahl</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Münchau</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Biscaldi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mainberger</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bäumer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rauh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mall</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Impaired induction of long-term potentiation-like plasticity in patients with high-functioning autism and Asperger syndrome</article-title>
<source/>Dev. Med. Child Neurol.
          <year>2013</year>
<volume>55</volume>
<fpage>83</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1111/dmcn.12012</pub-id>
<pub-id pub-id-type="pmid">23157428</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-18-00828">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modi</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Translational use of event-related potentials to assess circuit integrity in ASD</article-title>
<source/>Nat. Rev. Neurol.
          <year>2017</year>
<volume>13</volume>
<fpage>160</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1038/nrneurol.2017.15</pub-id>
<pub-id pub-id-type="pmid">28211449</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-18-00828">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmunk</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gargus</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>High-throughput screen detects calcium signaling dysfunction in typical sporadic autism spectrum disorder</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>40740</fpage>
<pub-id pub-id-type="doi">10.1038/srep40740</pub-id>
<pub-id pub-id-type="pmid">28145469</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-18-00828">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paşca</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Portmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Voineagu</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Yazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shcheglovitov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Paşca</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Cord</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Chikahisa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nishino</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome</article-title>
<source/>Nat. Med.
          <year>2011</year>
<volume>17</volume>
<fpage>1657</fpage>
<lpage>1662</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2576</pub-id>
<pub-id pub-id-type="pmid">22120178</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-18-00828">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.-J.J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhuo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Roles of calcium-stimulated adenylyl cyclase and calmodulin-dependent protein kinase {IV} in the regulation of {FMRP} by group I metabotropic glutamate receptors</article-title>
<source/>J. Neurosci.
          <year>2008</year>
<volume>28</volume>
<fpage>4385</fpage>
<lpage>4397</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0646-08.2008</pub-id>
<pub-id pub-id-type="pmid">18434517</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-18-00828">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waltes</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Duketis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Knapp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Anney</surname>
<given-names>R.J.L.</given-names>
</name>
<name>
<surname>Huguet</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schlitt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jarczok</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Sachse</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kämpfer</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Kleinböck</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders</article-title>
<source/>Hum. Genet.
          <year>2014</year>
<volume>133</volume>
<fpage>781</fpage>
<lpage>792</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-013-1416-y</pub-id>
<pub-id pub-id-type="pmid">24442360</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-18-00828">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pop</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Gomez-Mancilla</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Fragile X syndrome: A preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development</article-title>
<source/>Psychopharmacology
          <year>2014</year>
<volume>231</volume>
<fpage>1217</fpage>
<lpage>1226</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3330-3</pub-id>
<pub-id pub-id-type="pmid">24232444</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-18-00828">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ceolin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Perroy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huber Correspondence</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>Elevated CaMKIIα and Hyperphosphorylation of Homer Mediate Circuit Dysfunction in a Fragile X Syndrome Mouse Model</article-title>
<source/>Cell Rep.
          <year>2015</year>
<volume>13</volume>
<fpage>2297</fpage>
<lpage>2311</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2015.11.013</pub-id>
<pub-id pub-id-type="pmid">26670047</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-18-00828">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michalon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bruns</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Risterucci</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Honer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Ozmen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>von Kienlin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Künnecke</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Chronic Metabotropic Glutamate Receptor 5 Inhibition Corrects Local Alterations of Brain Activity and Improves Cognitive Performance in Fragile X Mice</article-title>
<source/>Biol. Psychiatry
          <year>2013</year>
<volume>75</volume>
<fpage>189</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.05.038</pub-id>
<pub-id pub-id-type="pmid">23910948</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-18-00828">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaefer</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Davenport</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Erickson</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Emerging pharmacologic treatment options for fragile X syndrome</article-title>
<source/>Appl. Clin. Genet.
          <year>2015</year>
<volume>2015</volume>
<fpage>75</fpage>
<lpage>93</lpage>
</element-citation>
</ref>
<ref id="B100-ijms-18-00828">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Coffey</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hervey</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yuhas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hutchison</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Snape</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tranfaglia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A pilot open label, single dose trial of fenobam in adults with fragile X syndrome</article-title>
<source/>J. Med. Genet.
          <year>2009</year>
<volume>46</volume>
<fpage>266</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2008.063701</pub-id>
<pub-id pub-id-type="pmid">19126569</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-18-00828">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sumis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hervey</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Porges</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Weiler</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Greenough</surname>
<given-names>W.T.</given-names>
</name>
</person-group>
<article-title>Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome</article-title>
<source/>J. Dev. Behav. Pediatr.
          <year>2008</year>
<volume>29</volume>
<fpage>293</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1097/DBP.0b013e31817dc447</pub-id>
<pub-id pub-id-type="pmid">18698192</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-18-00828">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weeber</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Varga</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Carrasquillo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Mirnikjoo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>A.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome</article-title>
<source/>J. Neurosci.
          <year>2003</year>
<volume>23</volume>
<fpage>2634</fpage>
<lpage>2644</lpage>
<pub-id pub-id-type="pmid">12684449</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-18-00828">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baucum</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Shonesy</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Colbran</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Quantitative Proteomics Analysis of CaMKII Phosphorylation and the CaMKII Interactome in the Mouse Forebrain</article-title>
<source/>ACS Chem. Neurosci.
          <year>2015</year>
<volume>6</volume>
<fpage>615</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="doi">10.1021/cn500337u</pub-id>
<pub-id pub-id-type="pmid">25650780</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-18-00828">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murakami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ichisaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oshiro</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Edenhofer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kiyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yonezawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells</article-title>
<source/>Mol. Cell. Biol.
          <year>2004</year>
<volume>24</volume>
<fpage>6710</fpage>
<lpage>6718</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.24.15.6710-6718.2004</pub-id>
<pub-id pub-id-type="pmid">15254238</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-18-00828">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takei</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nawa</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>mTOR signaling and its roles in normal and abnormal brain development</article-title>
<source/>Front. Mol. Neurosci.
          <year>2014</year>
<volume>7</volume>
<fpage>28</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2014.00028</pub-id>
<pub-id pub-id-type="pmid">24795562</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-18-00828">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Peñagarikano</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Belgard</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Swarup</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>The Emerging Picture of Autism Spectrum Disorder: Genetics and Pathology</article-title>
<source/>Annu. Rev. Pathol. Mech. Dis.
          <year>2015</year>
<volume>10</volume>
<fpage>111</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-pathol-012414-040405</pub-id>
<pub-id pub-id-type="pmid">25621659</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-18-00828">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McBride</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Varga</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Prior</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Manickam</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Atkin</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>G.E.</given-names>
</name>
</person-group>
<article-title>Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly</article-title>
<source/>Autism Res.
          <year>2010</year>
<volume>3</volume>
<fpage>137</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.1002/aur.132</pub-id>
<pub-id pub-id-type="pmid">20533527</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-18-00828">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plasschaert</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Descheemaeker</surname>
<given-names>M.-J.</given-names>
</name>
<name>
<surname>Van Eylen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Noens</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Steyaert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1</article-title>
<source/>Am. J. Med. Genet. Part B
          <year>2015</year>
<volume>168B</volume>
<fpage>72</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32280</pub-id>
<pub-id pub-id-type="pmid">25388972</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-18-00828">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoeffer</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Whelan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Zukin</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with Fragile X syndrome</article-title>
<source/>Genes Brain Behav.
          <year>2012</year>
<volume>11</volume>
<fpage>332</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2012.00768.x</pub-id>
<pub-id pub-id-type="pmid">22268788</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-18-00828">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Orlova</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Baybis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>A.W.S.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Birnbaum</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Estevez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Okochi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sarnat</surname>
<given-names>H.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fetal Brain mTOR Signaling Activation in Tuberous Sclerosis Complex</article-title>
<source/>Cereb. Cortex
          <year>2014</year>
<volume>24</volume>
<fpage>315</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhs310</pub-id>
<pub-id pub-id-type="pmid">23081885</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-18-00828">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kasai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takamatsu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hino</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mizuguchi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex</article-title>
<source/>Nat. Commun.
          <year>2012</year>
<volume>3</volume>
<fpage>1292</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms2295</pub-id>
<pub-id pub-id-type="pmid">23250422</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-18-00828">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Dasouki</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Talebizadeh</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.N.</given-names>
</name>
<name>
<surname>Miles</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Stratton</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pilarski</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations</article-title>
<source/>J. Med. Genet.
          <year>2005</year>
<volume>42</volume>
<fpage>318</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2004.024646</pub-id>
<pub-id pub-id-type="pmid">15805158</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-18-00828">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Luikart</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Matheny</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>L.F.</given-names>
</name>
</person-group>
<article-title>Pten Regulates Neuronal Arborization and Social Interaction in Mice</article-title>
<source/>Neuron
          <year>2006</year>
<volume>50</volume>
<fpage>377</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2006.03.023</pub-id>
<pub-id pub-id-type="pmid">16675393</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-18-00828">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cupolillo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hoxha</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Faralli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tempia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Carulli</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Autistic-Like Traits and Cerebellar Dysfunction in Purkinje Cell PTEN Knock-Out Mice</article-title>
<source/>Neuropsychopharmacology
          <year>2015</year>
<volume>41</volume>
<fpage>1</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2015.339</pub-id>
<pub-id pub-id-type="pmid">26538449</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-18-00828">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johannessen</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Reczek</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cichowski</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The NF1 tumor suppressor critically regulates TSC2 and mTOR</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2005</year>
<volume>102</volume>
<fpage>8573</fpage>
<lpage>8578</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0503224102</pub-id>
<pub-id pub-id-type="pmid">15937108</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-18-00828">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burket</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Benson</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Deutsch</surname>
<given-names>S.I.</given-names>
</name>
</person-group>
<article-title>Rapamycin improves sociability in the BTBR T+itpr3tf/J mouse model of autism spectrum disorders</article-title>
<source/>Brain Res. Bull.
          <year>2014</year>
<volume>100</volume>
<fpage>70</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresbull.2013.11.005</pub-id>
<pub-id pub-id-type="pmid">24295733</pub-id>
</element-citation>
</ref>
<ref id="B117-ijms-18-00828">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berry</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bindocci</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alleva</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>NGF, Brain and Behavioral Plasticity</article-title>
<source/>Neural Plast.
          <year>2012</year>
<volume>2012</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1155/2012/784040</pub-id>
<pub-id pub-id-type="pmid">22474604</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-18-00828">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gnahn</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hefti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Heumann</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Thoenen</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>NGF-Mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: Evidence for a physiological role of NGF in the brain?</article-title>
<source/>Dev. Brain Res.
          <year>1983</year>
<volume>9</volume>
<fpage>45</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1016/0165-3806(83)90107-4</pub-id>
</element-citation>
</ref>
<ref id="B119-ijms-18-00828">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Holtzman</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Kromer</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Chua-Couzens</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Clary</surname>
<given-names>D.O.</given-names>
</name>
<name>
<surname>Knüsel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mobley</surname>
<given-names>W.C.</given-names>
</name>
</person-group>
<article-title>Regulation of TrkA and ChAT expression in developing rat basal forebrain: Evidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons</article-title>
<source/>J. Neurosci.
          <year>1995</year>
<volume>15</volume>
<fpage>2888</fpage>
<lpage>2905</lpage>
<pub-id pub-id-type="pmid">7536822</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-18-00828">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riikonen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vanhala</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Levels of cerebrospinal fluid nerve-growth factor differ in infantile autism and Rett syndrome</article-title>
<source/>Dev. Med. Child Neurol.
          <year>1999</year>
<volume>41</volume>
<fpage>148</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162299000328</pub-id>
<pub-id pub-id-type="pmid">10210246</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-18-00828">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Grether</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Croen</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Dambrosia</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Dickens</surname>
<given-names>B.F.</given-names>
</name>
<name>
<surname>Jelliffe</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>T.M.</given-names>
</name>
</person-group>
<article-title>Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation</article-title>
<source/>Ann. Neurol.
          <year>2001</year>
<volume>49</volume>
<fpage>597</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1002/ana.1024</pub-id>
<pub-id pub-id-type="pmid">11357950</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-18-00828">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamova</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nordahl</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>F.R.</given-names>
</name>
</person-group>
<article-title>Evidence for differential alternative splicing in blood of young boys with autism spectrum disorders</article-title>
<source/>Mol. Autism
          <year>2013</year>
<volume>4</volume>
<fpage>30</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-4-30</pub-id>
<pub-id pub-id-type="pmid">24007566</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-18-00828">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakrabarti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dudbridge</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kent</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wheelwright</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hill-Cawthorne</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Allison</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Banerjee-Basu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Genes related to sex steroids, neural growth, and social-emotional behavior are associated with autistic traits, empathy, and asperger syndrome</article-title>
<source/>Autism Res.
          <year>2009</year>
<volume>2</volume>
<fpage>157</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1002/aur.80</pub-id>
<pub-id pub-id-type="pmid">19598235</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-18-00828">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>A.T.-H.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Cantor</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>QTL replication and targeted association highlight the nerve growth factor gene for nonverbal communication deficits in autism spectrum disorders</article-title>
<source/>Mol. Psychiatry
          <year>2013</year>
<volume>18</volume>
<fpage>226</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2011.155</pub-id>
<pub-id pub-id-type="pmid">22105621</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-18-00828">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellegood</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Anagnostou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Babineau</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Genestine</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>DiCicco-Bloom</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>J.K.Y.</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Peñagarikano</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clustering autism: Using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity</article-title>
<source/>Mol. Psychiatry
          <year>2015</year>
<volume>20</volume>
<fpage>118</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2014.98</pub-id>
<pub-id pub-id-type="pmid">25199916</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-18-00828">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>C.-S.</given-names>
</name>
<name>
<surname>Kaang</surname>
<given-names>B.-K.</given-names>
</name>
</person-group>
<article-title>Neuronal mechanisms and circuits underlying repetitive behaviors in mouse models of autism spectrum disorder</article-title>
<source/>Behav. Brain Funct.
          <year>2016</year>
<volume>12</volume>
<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/s12993-016-0087-y</pub-id>
<pub-id pub-id-type="pmid">26790724</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>